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Unwarranted Variation in the Quality of Care for Patients With
Diseases of the Thoracic Aorta
Alex Bottle, MSc, PhD;* Giovanni Mariscalco, MD, PhD;* Matthew A. Shaw, MA; Umberto Benedetto, MD; Athanasios Saratzis, MD;
Silvia Mariani, MD; Mohamad Bashir, MD, MRCS, PhD; Paul Aylin, FFPH; David Jenkins, BSc, MBBS, FRCS, MS; Aung Y. Oo, FRCS;
Gavin J. Murphy, MD, FRCS; on behalf of the UK Aortic Forum†
Background-—Thoracic aortic disease has a high mortality. We sought to establish the contribution of unwarranted variation in care
to regional differences in outcomes observed in patients with thoracic aortic disease in England.
Methods and Results-—Data from the Hospital Episode Statistics (HES) and the National Adult Cardiac Surgery Audit (NACSA)
were extracted. A parallel systematic review/meta-analysis through December 2015, and structure and process questionnaire of
English cardiac surgery units were also accomplished. Treatment and mortality rates were investigated. A total of 24 548 adult
patients in the HES study, 8058 in the NACSA study, and 103 543 from a total of 33 studies in the systematic review were
obtained. Treatment rates for thoracic aortic disease within 6 months of index admission ranged from 7.6% to 31.5% between
English counties. Risk-adjusted 6-month mortality in untreated patients ranged from 19.4% to 36.3%. Regional variation persisted
after adjustment for disease or patient factors. Regional cardiac units with higher case volumes treated more-complex patients and
had signiﬁcantly lower risk-adjusted mortality relative to low-volume units. The results of the systematic review indicated that the
delivery of care by multidisciplinary teams in high-volume units resulted in better outcomes. The observational analyses and the
online survey indicated that this is not how services are conﬁgured in most units in England.
Conclusions-—Changes in the organization of services that address unwarranted variation in the provision of care for patients with
thoracic aortic disease in England may result in more-equitable access to treatment and improved outcomes. ( J Am Heart Assoc.
2017;6:e004913. DOI: 10.1161/JAHA.116.004913.)
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D iseases of the thoracic aorta are increasing in preva-lence worldwide.1,2 In the United Kingdom (UK),
between 1999 and 2010, hospital admissions for thoracic
aortic dissection increased from 7.2 to 8.8 and for thoracic
aortic aneurysm from 4.4 to 9.0 per 100 000 inhabitants.3
These diseases have a high mortality; in the UK, mortality
rates for thoracic aortic dissection and aneurysm are 3.2 and
7.5 per 100 000 inhabitants, respectively.3 There is evidence
of regional variation in clinical outcomes for patients with
thoracic aortic disease (TAD)4–11; for example, operative
mortality rates for acute type A dissection, the most common
acute presentation of TAD, range from 2.8% to 47.6% between
centers.4,9–16 This may reﬂect differences in socioeconomic,
ethnic, and other demographic characteristics of local pop-
ulations, but there is also evidence of variation in the
provision of aortic services in the UK and elsewhere.7,10,16
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Targeting unwarranted variation is a key objective for health
services as a means of improving the quality and equity of
access to care.17
The aim of the current study was to evaluate the contribu-
tion of unwarranted variations in care to regional differences in
outcome observed in TAD patients in England and identify
areas of structure and process for quality improvement.
Methods
Study Design
We measured mortality (primary outcome) along with a range
of other important measures of quality, such as equity of
access, timeliness of surgery, and the effect of treatment on
longer-term patient outcomes in national databases used to
monitor quality of care by National Health Service (NHS)
England; the National Adult Cardiac Surgery Audit (NACSA),
used by the National Institute for Comparative Outcomes
Research (NICOR) to monitor cardiac surgeon and unit
speciﬁc hospital mortality, and the administrative NHS
database Hospital Episode Statistics (HES), used by Dr Foster
to measure hospital performance. We also asked cardiac
surgical units in England to complete a questionnaire on the
structure and organization of TAD services. Because there is
no agreed service speciﬁcation for TAD services in England
and elsewhere,7,10,16,18,19 and current recommendations for
service organization are not evidence based,20–24 we also
conducted a parallel systematic review of existing studies that
have considered quality standards for TAD service delivery.
Data were extracted from the HES and the NICOR NACSA
registry, according to The REporting of studies Conducted
using Observational Routinely collected health Data (RECORD)
statement (Table S1).25 The need to obtain informed consent
from patients was waived by the University of Leicester
Research Governance Ofﬁce because the identiﬁable infor-
mation was either removed or pseudonymized. The study was
approved by the NICOR NACSA Research Board (study
reference 14-ACS-25). A systematic review and meta-analysis
on the standard of care for the management of TAD was also
performed and adhered to MOOSE and PRISMA guidelines
(Tables S2 and S3).26,27
Data Sources and Study Populations
Data, outcomes, and study populations obtained from HES and
NICOR NACSA registries are fully reported in Data S1. Brieﬂy,
HES is the national hospital administrative database for
England and covers all admissions to public (NHS) hospitals
in the country.28 The data contain demographic, administrative,
and clinical information, including procedures and operations
(Table S4). The NICOR NACSA registry (version 4.1.2) contains
prospectively data for all English adult patients undergoing
major thoracic aortic surgery and undergoes robust validation
and checking procedures to maintain data quality.16,29–31
To complement the NACSA study, we also contacted the
Society for Cardiothoracic Surgery Unit Representatives for
every cardiac surgery unit in England assessing their current
service organization for TAD. Surgeons were queried on the
presence of a dedicated aortic team, a speciﬁc on-call rota for
thoracic aortic disease, a hybrid theater, and an aortic
multidisciplinary team (MDT) recognized in the consultant job
plan.
The study was approved by the NICOR NACSA Research
Board (study reference 14-ACS-25). The need to obtain
informed consent from patients was waived by the University
of Leicester Research Governance Ofﬁce because the iden-
tiﬁable information was either removed or pseudonymized.
Systematic Review and Meta-Analysis
Electronic search strategy, objectives, criteria for study
selection, eligibility, data collection, and assessment of study
quality were published online and registered in the PROSPERO
International Prospective Register of Systematic Reviews
(PROSPERO registry—CRD42015024137).32
Brieﬂy, 3 reviewers systematically searched electronic
databases (MEDLINE [PubMed and Ovid], Embase, SCOPUS,
and Cochrane Library) without date or language restriction
from inception to the end of December 2015. Our keywords
and MeSH terms pertinent to the exposure of interest were
used in relevant combinations and included: “aorta”, “aorta,
thoracic”, “aorta, thoracoabdominal”, “aortic aneurysm”, “aor-
tic dissection”, “standard of care”, “health care”, “treatment
outcome”, “hospital mortality”, “hospital volume”, “surgeon
volume”, “volume outcome relationship”, “teaching hospital”,
and “urban hospital”. In addition, the reference lists of all
retrieved articles were reviewed for further identiﬁcation of
potentially relevant studies that were not previously identiﬁed.
All adult major thoracic aortic procedures were considered.
Exposures of interest included hospital volume activity,
generally deﬁned as yearly number of major aortic operations
performed, subdivided in low- or high-volume, surgeon
volume, presence of multidisciplinary thoracic aortic surgery
program, and teaching/urban hospital status. The primary
outcome of interest was all-cause mortality in hospital or
within 30 days from index admission or procedure. Secondary
outcomes included postoperative stroke, re-exploration for
bleeding/tamponade, postoperative renal failure, and total
length of hospital stay. Inclusion and exclusion criteria for
qualitative/quantitative analyses were summarized according
to PICOS approach (Table S5).
Year of publication, study design, country, sample size,
recruitment period, inclusion and exclusion criteria, measured
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outcomes, aortic center conﬁguration, and deﬁnition of low-
and high-volume threshold, baseline patient demographics
(age, sex), and outcomes among low- and high-volume groups
were extracted. Quality assessment was performed using the
Newcastle-Ottawa Scale (NOS).33
Statistical Analysis
HES cohort
Outcomes were calculated as crude proportions and adjusted
for a number of patient factors as listed in Tables S6 and S7.
Comorbidity information was taken from the index admission
or any admission for any reason in the previous year. All
outcomes were binary, so logistic regression was used. These
models were hierarchical with 2 levels, with random effects
for each county. Predicted probabilities for each patient were
derived from the ﬁxed-effects part of the model.34 Hierarchi-
cal models adjust for the clustering of patients within county
and allow the estimation of the proportion of variation in the
outcome that is attributable to each level of the model (ie, to
patient factors and to county). To obtain adjusted outcome
rates by county, observed and predicted probabilities were
summed by county, with the former divided by the latter to
obtain relative risks. These were then multiplied by the
national crude outcome rate to obtain adjusted rates. Rates
were put onto funnel plots with 95% and 99.8% control limits,
the latter to determine how many counties were statistical
outliers. To assess model ﬁt, deviance residuals were plotted
and the Hosmer-Lemeshow risk deciles and chi-squared value
also inspected. Discrimination was assessed using the area
under the receiver-operating characteristic curve (c statistic).
This was done for logistic regression without adjustment for
clustering, because there is no consensus over how to
calculate the equivalent measures for hierarchical models.35
As well as random effects for each geographical area, random
slopes were tried in the model for receiving surgery for several
binary patient factors: age over 75 versus younger, 1 or more
versus none of 5 major comorbidities, dissection versus none,
and aneurysm versus none. This was to see whether any of
these factors had different effects on the outcome depending
on the area. We did not ﬁnd such effects and therefore report
only results from using ﬁxed slopes. Finally, obtained rates for
TAD treatment by county as well as 6-month mortality for
treated and untreated patients were mapped using ArcMap
version 10.3 (ESRI, Redlands, CA).
NACSA cohort
Categorical and dichotomous variables were summarized as
absolute number and percentage. Non-normally distributed
continuous data were summarized as medians and interquar-
tile ranges (IQRs). The effects of operational and institutional
characteristics on in-hospital mortality were assessed using
multiple logistic regression models. Relevant patient-level
variables were offered to the models to adjust for any potential
confounding factors. Results of the regression analyses were
expressed as odds ratios (ORs) and 95% CIs. Box and whisker
plots were used to present case mix distributions by center:
These plots show the 25th percentile, median and 75th
percentile of a given distribution at the bottom, middle and top
of the boxes, respectively, then the mean is then plotted as a
dot, and the lower and upper whiskers then represent the 5th
and 95th percentiles, respectively. Scatter plots were gener-
ated to assess the relationship between observed in-hospital
mortality and volume, and ordinary least squares (OLS)
regression lines were included for visual inspection. Statistical
analyses were performed with SAS software (version 9.3; SAS
Institute Inc., Cary, NC). In all cases, P<0.05 was considered
statistically signiﬁcant.
Systematic review and meta-analysis
Treatment effect on operative outcomes is reported as ORs
with a 95% CI. Yates correction was implemented if a cell
contained a zero in the 292 contingency table.36 Individual
ORs (OR <1: high volume centers better) and variance were
computed by using number of events and sample size and
pooled by using Mantel–Haenszel method and random-effects
model.37 A ﬁxed-effects model was also computed as
sensitivity analysis. A subgroup analysis according to the
primary aortic pathology (aneurysm vs aortic dissection) was
performed, being a possible signiﬁcant effect modiﬁer. Finally,
to account for inherent patient selection bias related with an
observational study design, individual risk-adjusted ORs for
the primary endpoint were obtained when reported, and
pooled adjusted risk estimates were computed by using log
transformation and a generic inverse-variance weighting
method. I2 statistic was used to estimate the percentage of
total variation across studies attributed to heterogeneity
rather than chance. Suggested thresholds for heterogeneity
were used, with I2 values of 25% to 49%, 50% to 74%, and
≥75%, indicative of low, moderate, and high heterogeneity.38
Publication bias was evaluated using visual inspection of
funnel plot asymmetry and by Egger’s test.39 P<0.05 was
used as the level of signiﬁcance and 95% CIs were reported
where appropriate. Statistical analysis was conducted using
meta package for R (version 4.3-2; R Foundation for Statistical
Computing, Vienna, Austria).40,41
Results
HES Cohort
Of 26 551 patients with a TAD admission in England between
2004–2005 and 2010–2011, 25 282 had not had such an
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admission in the previous 5 years and were deﬁned as index
admissions. Seven hundred thirty-four (2.8%) were excluded
because of lack of area identiﬁers, leaving a ﬁnal population of
24 548 adult patients coded as having a new diagnosis of
TAD. Of these, 16 448 (67%) were affected by aneurysms,
6345 (25.9%) by dissections, and 1665 (6.8%) by unspeciﬁed
TAD. A total of 5445 (22%) underwent treatment (surgical
and/or endovascular) within 6 months of diagnosis. The 6-
month mortality in treated patients was 17.7% and in
untreated patients was 30%. Patient characteristics are
summarized in Table 1.
Variation attributable to patient-related factors
Predictive variables for receiving treatment, or an emergent
procedure, are reported in Table S6. Brieﬂy, increasing age,
pre-existing diabetes mellitus, comorbidities, and a diagnosis
of cancer were associated with a conservative approach. The
greater the deprivation status, the lower were the odds of
being treated. Patients affected by aortic dissection and
comorbid conditions, including ischemic heart disease and
congenital and other vascular disorders, were more prone to
be treated on an emergent basis. Predictors of 6-month
mortality in treated and untreated patients are summarized in
Table S7. In patients receiving treatment, mortality was
associated with increasing age, comorbidity presence, and
nonelective admission. Emergent/urgent admission,
increasing age, severe comorbidity, and the presence of
aortic dissection were associated with mortality in untreated
patients.
Variation attributable to non-patient-related factors
Signiﬁcant variance by county of residence was observed in
terms of the percentages of patients receiving treatment
within 6 months of their index admission, ranging from 7.6%
in Leicestershire to 31.5% in the West Midlands (Figure 1).
The percentage of subjects treated emergently ranged from
29.6% in Merseyside to 67.9% in Durham (Figure 2). Multilevel
modeling conﬁrmed the statistically signiﬁcant differences in
treatment rates by county of residence. A null model
containing only random effects for the counties estimated
the variance between counties in log odds of treatment as
0.096 (SE, 0.024); adding patient factors to this null model
actually increased the estimated between-county variance (to
0.105; SE, 0.026). To adjust for regional differences in
detection rates, the TAD admission rates per 100 000
resident populations for each county were entered into the
model. This reduced the between-county variance in treat-
ment rates by 40% to 0.060 (SE, 0.016). Despite this, the
overall number of counties ﬂagged as high or low outliers on
funnel plots using 99.8% control limits were very similar to
those observed using crude TAD admission rates.
Regional differences by county were also observed for 6-
month mortality (Figure 1 and Figure S1). For treated
patients, risk-adjusted mortality rates ranged from 6.5% in
Oxfordshire to 23.3% in North Yorkshire. Risk-adjusted
mortality rates in untreated patients ranged from 19.4% in
Leicestershire to 36.3% in East Sussex. Adding patient factors
to the null model reduced the variation in mortality in treated
patients attributable to county of origin by 27%, therefore
becoming nonsigniﬁcant (variance estimate, 0.037; SE,
0.023). A 62% fall in the variation in mortality was observed
in untreated patients, although the between-county variance
remained statistically signiﬁcantly greater than zero, but
modest in size (0.027; SE, 0.009).
Using Pearson correlation with counties weighted by their
total number of index admissions, we compared the sets of
county-level adjusted outcome rates. The proportion of
patients receiving treatment showed positive, but nonsignif-
icant, correlations with the proportion of treatments done
nonemergently (q=+0.20; P=0.209) and the postoperative
mortality rate (q=+0.25; P=0.114). Conversely, the proportion
of treated patients demonstrated a positive and statistically
signiﬁcant correlation with the mortality rate in untreated
patients (q=+0.47; P=0.002). This latter relation was driven
by patients without dissection: for these patients alone, the
correlation was +0.68 (P<0.001), whereas for those with
dissection it was 0.28 (P=0.079). In order to verify whether
the positive correlation between treatment rates and 6-month
Table 1. National Crude Outcome Rates Split by Age, Major
Comorbidity, and TAD Subtype (HES Cohort)
Patient Factor*
Receiving
Operation
(%)
Nonemergent
Operation
(%)
Postoperative
Mortality
(%)
Mortality
in Patients
With No
Operation
(%)
Age <75, y 31.6 54.4 14.0 18.4
Age 75+, y 11.6 52.6 24.3 40.7
TAD:
dissection
19.4 10.9 21.5 39.9
TAD:
aneurysm
15.8 69.3 12.5 26.4
No major
comorbidity
27.6 50.1 12.2 27.6
1+ major
comorbidities
18.8 58.2 21.0 31.7
All patients
combined
22.2 53.7 16.7 30.5
HES indicates Hospital Episodes Statistics; TAD, thoracic aortic disease.
*Patients with neither dissection nor aneurysm recorded have been omitted from the
rows for TAD subtype. Major comorbidities covered ischemic heart disease,
cerebrovascular disease, chronic obstructive pulmonary disease, renal disease, and
cancer. Mortality is deﬁned as death in or out of hospital within 6 months of diagnosis or
operation.
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mortality in both treated and untreated patients may reﬂect
an underlying difference in access to care, patients’ risk
proﬁles were analyzed. No correlation between the proportion
of high-risk patients treated by county, deﬁned as those in the
highest tertile for predicted probability, and mortality rate in
the untreated was observed (q=+0.17; P=0.294).
Operation Rates (%)
7.6 - 16.5
16.5 - 21.8
21 8 25 1
Six-month Mortality (%)
Treated Patients
6.6 - 11.9
11.9 - 16.3
16 3 20 1
12.8 - 22.4
22.4 - 30.9
Six-month Mortality (%)
Untreated Patients
.  - .
25.1 - 27.7
27.7 - 31.5
.  - .
20.1 - 23.8
23.8 - 26.6
30.9 - 34.7
34.7 - 38.4
38.4 - 44.8
Figure 1. Geographical variation by county across England with reference to treatment rates in patients diagnosed with thoracic aortic disease
(left panel), 6-month mortality in treated (mid panel) and untreated (right panel) patients. From HES (Hospital Episodes Statistics) cohort data.
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Figure 2. Percentage of patients affected by thoracic aortic disease (TAD) by county and urgency of the
operation received (elective vs emergent). From HES (Hospital Episodes Statistics) cohort data.
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Table 2. Baseline, Operative, and Mortality Details by Center Volume (Tertiles of Latest 3-Year Activity) (NACSA Cohort)
Patient Factor*
Low-Volume
Center (n=1308)
Medium-Volume
Center (n=2159)
High-Volume
Center (n=4591)
Demographics
Age at operation, y 64 (52, 72) 64 (52, 73) 64 (51, 73)
BMI, kg/m2 27.2 (24.4, 30.2) 27.0 (24.1, 30.4) 26.7 (23.9, 29.9)
Female sex 450 (34.4) 715 (33.1) 1526 (33.2)
Comorbidities
Unstable angina 77 (5.9) 114 (5.3) 181 (3.9)
NYHA ≥III 411 (31.4) 721 (33.4) 1184 (25.8)
MI within 90 days of operation 58 (4.4) 72 (3.3) 138 (3.0)
Previous cardiac surgery 150 (11.5) 307 (14.2) 795 (17.3)
Previous aortic surgery 27 (2.1) 71 (3.3) 237 (5.2)
Diabetes mellitus 102 (7.8) 175 (8.1) 276 (6.0)
Current smoker 166 (12.7) 236 (12.2) 478 (10.4)
Hypertension 838 (64.1) 1419 (65.7) 2779 (60.5)
Creatinine >200 lmol/L 39 (3.0) 62 (2.9) 123 (2.7)
History of renal dysfunction 16 (1.2) 37 (1.7) 81 (1.8)
History of pulmonary disease 153 (11.7) 267 (12.4) 554 (12.1)
History of stroke 119 (9.1) 192 (8.9) 350 (7.6)
Neurological dysfunction 55 (4.2) 91 (4.2) 160 (3.5)
Peripheral vascular disease 213 (16.3) 452 (20.9) 647 (14.1)
Preoperative nonsinus heart rhythm 182 (13.9) 278 (12.9) 478 (10.4)
Triple vessel disease 68 (5.2) 134 (6.2) 169 (3.7)
Left main stem disease 30 (2.3) 45 (2.1) 77 (1.7)
Moderate ejection fraction
(30–50%)
308 (23.6) 419 (19.4) 857 (18.7)
Poor ejection fraction (<30%) 57 (4.4) 92 (4.3) 179 (3.9)
PA systolic >60 mm Hg 26 (2.0) 26 (1.2) 42 (0.9)
Preoperative IV nitrates 62 (4.7) 118 (5.5) 231 (5.0)
Preoperative IV inotropes 35 (2.7) 58 (2.7) 133 (2.9)
Preoperative ventilation 22 (1.7) 42 (2.0) 102 (2.2)
Preoperative cardiogenic shock 88 (6.7) 100 (4.6) 154 (3.4)
Nonelective priority 497 (38.0) 801 (37.1) 1643 (35.8)
Urgent priority 202 (15.4) 396 (18.3) 697 (15.2)
Emergency priority 267 (20.4) 355 (16.4) 888 (19.3)
Salvage priority 28 (2.1) 50 (2.3) 58 (1.3)
Dominant pathology
Aneurysm 697 (53.3) 1248 (57.8) 2477 (54.0)
Dissection 326 (24.9) 481 (22.3) 1012 (22.0)
Trauma 7 (0.5) 7 (0.3) 36 (0.8)
“Other” 166 (12.7) 366 (17.0) 702 (15.3)
Data N/A 112 (8.6) 57 (2.6) 364 (7.9)
Continued
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NACSA Cohort
We considered that confounders not contained within HES
data might also contribute to unwarranted variance. We
therefore evaluated regional variance in treatment of TAD
using the NACSA registry, which contains validated data on
the severity and complexity as well as the treatment of TAD
by regional cardiac centers.
Study cohort
Of the 219 741 patients that underwent surgery in cardiac
surgery centers in England, complete case data were available
on 8058 major aortic surgery cases from 29 hospitals that
comprised the analysis data set. Patient characteristics and
operative details are summarized in Table 2 and Table S8. All
centers provided data on patients operated on root/ascend-
ing aorta and aortic arch segments, 28 (96.6%) centers on the
descending thoracic aorta, and 17 (58.6%) on the thoracoab-
dominal aorta (Figure 3).
Variation attributable to patient-related factors
There were differences between centers with respect to
predicted operative risk (Figure 3C); the median calculated
logistic EuroSCORE of in-hospital mortality ranged from 4.6%
to 9.1%. Pathology, emergent treatment, and the most distal
aortic surgery segment treated (case complexity) were
important determinants of hospital mortality (Table 3).
Variation attributable to non-patient-related factors
There were differences between centers with respect to the
complexity and volume of cases performed. The largest
volume of cases by a single center was 662 and the smallest
117 (Figure 3A). The percentage of root/ascending aortic
operations as a share of total aortic operations ranged from
45.1% to 96.0%, for aortic arch procedures the range was
from 1.7% to 32.1%, for descending thoracic aortic procedures
from 0.7% to 18.7%, and for thoracoabdominal aortic proce-
dures from 0.2% to 9.9% (Table S9 and Figure S2). More-
complex surgery was more common in high-volume centers.
The results of the survey of service organization are shown
alongside details of case volume, complexity, and outcome by
unit in Figure 3D. All the units responded to the question-
naire. This demonstrated regional variation in care delivery in
terms of the presence of dedicated aortic teams, multidisci-
plinary aortic team meetings, speciﬁc on-call rotas for aortic
emergencies, or use of hybrid operating theaters.
Table 3 and Table S10 show unadjusted and fully risk-
adjusted in-hospital mortality effects by operation category,
tertile of volume activity, dominant pathology, and priority.
Case complexity was a principal determinant of in-hospital
mortality. Relative to proximal segments (root/ascending) the
adjusted ORs for aortic arch procedures as well as descending
thoracic and thoracoabdominal aortic procedures were 1.88
(95% CI, 1.48–2.37), 2.47 (95% CI, 1.77–3.44), and 3.05 (95%
CI, 1.82–5.11), respectively. For the increasing volume
Table 2. Continued
Patient Factor*
Low-Volume
Center (n=1308)
Medium-Volume
Center (n=2159)
High-Volume
Center (n=4591)
Aortic segment
Root/ascending aorta 1211 (92.6) 1798 (83.3) 3839 (83.6)
Aortic arch 75 (5.7) 275 (12.7) 412 (9.0)
Descending aorta 17 (1.3) 58 (2.7) 245 (5.3)
Thoracoabdominal aorta 5 (0.4) 28 (1.3) 95 (2.1)
Surgical data
Concomitant valve operation 948 (72.5) 1339 (62.0) 3032 (66.0)
Concomitant CABG operation 237 (18.1) 399 (18.5) 846 (18.4)
Concomitant “other” cardiac operation 510 (39.0) 728 (33.7) 1408 (30.7)
CPB time, min 178 (129, 240) 152 (114, 208) 162 (116, 229)
ACC time, min 114 (82, 154) 104 (74, 136) 105 (75, 143)
Circulatory arrest time, min 26 (18, 37) 25 (17, 34) 27 (18, 39)
Outcome
In-hospital mortality 138 (10.6) 206 (9.5) 404 (8.8)
ACC indicates aortic cross-clamp; BMI, body mass index; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; IV, intravenous; NACSA, National Adult Cardiac Surgery
audit; N/A, not available; NYHA, New York Heart Association; PA, pulmonary artery.
*Numerical data are expressed as median and interquartile range (IQR); categorical data as absolute number (percentage).
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Figure 3. Activity (total number of procedures) (A) and in-hospital mortality rate (B) by center, by most
distal aortic segment; patient risk proﬁle by center expressed by EuroSCORE II (C). From NACSA (National
Adult Cardiac Surgery Audit) cohort data. Results of the national survey assessing current service
organization for thoracic aortic disease in cardiac surgery centers across England; surgeons were queried on
the presence of a dedicated aortic team, a speciﬁc on-call rota for thoracic aortic disease, a hybrid theater,
and an aortic multidisciplinary team (MDT) recognized in the consultant job plan (D): The presence of a
vertical bar for a given center means that that center had the particular feature given in the chart key.
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activity tertiles, the corresponding adjusted risk of in-hospital
mortality relative to low-volume centers was 0.84 (95% CI,
0.66–1.07) for medium-volume centers and 0.72 (95% CI,
0.57–0.89) for high-volume centers (Table 4). Similar results
were observed when cases where stratiﬁed by most distal
segment, as well for the OLS regression analyses that
demonstrated lower mortality in centers with high-volume
activity (Figure S3).
Systematic Review and Meta-Analysis
Of the 12 804 records identiﬁed, 33 eligible observational
cohort studies were included in the systematic review,
comprising a total of 103 543 patients (Figure S4).6–14,42–67
The identiﬁed studies (20 multicenter and 13 single-center)
were published between 1994 and 2015. Study characteris-
tics and collected study outcomes are summarized in Tables
S11 through S13. Quality assessment indicated that 20 of 33
studies were at signiﬁcant risk of bias (NOS, <8; Table S14).
Twelve observational cohort studies analyzing impact of
hospital volume on in-hospital mortality were identiﬁed for
the primary analysis, including a total of 14 562 and 16 036
patients who underwent surgery in high- and low-volume
centers, respectively. Pooled unadjusted ORs showed that
high-volume centers were associated with a 50% relative risk
reduction in mortality when compared with low-volume
centers (Figure 4, upper panel),* with a moderate hetero-
geneity among studies (I2=53.4%). No publication bias was
found (P=0.19; Figure S5). Overall, 9 studies reported on
adjusted effect size of hospital volume on mortality
(Table S15). Pooled adjusted estimates of individual log ORs
conﬁrmed that high-volume centers were independently
associated with a signiﬁcantly reduced incidence of in-
hospital/30-day mortality (adjusted OR, 0.56; 95% CI, 0.45–
0.70; I2=70.2%; Figure 4 lower panel).7,8,10,13,50,58–60,62 Sub-
group analysis showed similar effects for high-volume centers
with respect to both aneurysms and aortic dissection
(Figure S6). Pooled estimates did not reveal any signiﬁcant
differences between high- and low-volume centers with
reference to postoperative stroke (OR, 1.29; 95% CI, 0.85–
1.95; I2=58.8%), re-exploration for bleeding/tamponade (OR,
0.91; 95% CI, 0.72–1.15; I2=68.5%), and postoperative renal
failure (OR, 0.82; 95% CI, 0.65–1.04; I2=77.6%; Figure S7).
Centers that introduced a speciﬁc multidisciplinary TAD
program also reported a signiﬁcant reduction in mortality
Table 3. Unadjusted and Risk-Adjusted In-Hospital Mortality Effects (NACSA Cohort)
Frequency
Observed
Mortality (%)
Unadjusted
OR (95% CI)
Adjusted
OR (95% CI)
Aortic segment*
Root/ascending aorta 6848 8.3 Reference Reference
Aortic arch 762 13.3 1.75 (1.42, 2.16) 1.86 (1.47, 2.35)
Descending aorta 320 15.3 1.86 (1.38, 2.51) 2.30 (1.66, 3.18)
Thoracoabdominal aorta 128 22.7 1.91 (1.18, 3.09) 2.75 (1.67, 4.56)
Activity tertile†
Low-volume (latest 3 years’ activity) 1308 10.6 Reference Reference
Medium-volume (latest 3 years’ activity) 2159 9.5 0.89 (0.71, 1.12) 0.80 (0.62, 1.02)
High-volume (latest 3 years’ activity) 4591 8.8 0.82 (0.67, 1.00) 0.76 (0.60, 0.95)
Dominant pathology‡
Aneurysm 4422 4.9 Reference Reference
Dissection 1819 17.2 4.07 (3.39, 4.89) 2.27 (1.82, 2.82)
Other 1284 13.2 2.97 (2.40, 3.67) 2.05 (1.61, 2.61)
Data N/A 533 9.6 2.07 (1.50, 2.85) 1.78 (1.26, 2.52)
Priority†
Elective 5117 4.8 Reference Reference
Nonelective 2941 17.1 4.08 (3.47, 4.78) 2.54 (2.09, 3.08)
*Adjusted for preoperative comorbidities, operative risk factors, and activity tertile.
†Adjusted for preoperative comorbidities, operative risk factors, and most distal aortic segment.
‡Adjusted for preoperative comorbidities, operative risk factors, most distal aortic segment, and activity tertile.
*References: 7–10, 13, 50, 58–60, 62, 65, 66.
DOI: 10.1161/JAHA.116.004913 Journal of the American Heart Association 9
Quality of Care Variation in Thoracic Aorta Disease Mariscalco et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on January 24, 2019
(OR, 0.35; 95% CI, 0.13–0.96) although with signiﬁcant
heterogeneity (I2=75.7%; Figure S8). Surgeon volume (high- vs
low-volume surgeon) and hospital status (teaching vs non-
teaching hospitals and urban vs rural hospitals) had no effect
on hospital outcomes (Figures S9 and S10).
Discussion
The current study has demonstrated signiﬁcant regional
variation in access to treatment, the organization of clinical
services, and mortality for patients with TAD in England. An
analysis of HES data demonstrated that the variation in the
proportion of TAD patients treated within 6 months of
diagnosis ranged from 7.6% to 31.5% among counties and
remained statistically signiﬁcant after adjustment for poten-
tial confounders, including comorbidity, deprivation, disease
severity, and population density. Regional variation was not
associated with differences in mortality rates for patients that
received treatment, but was associated with differences in
mortality in those that did not receive treatment, implying
that inequity in access to care has important effects on
outcome. The analysis of NASCA data indicated wide regional
variation in the volume and complexity of TAD cases
undertaken in English cardiac centers. Centers undertaking
higher volumes were more likely to treat more-complex
disease and had lower risk-adjusted mortality. A systematic
review that attempted to benchmark service speciﬁcations
for TAD indicated that patients treated by multidisciplinary
teams in high-volume centers have better clinical outcomes.
A survey of structure and processes indicated that this
standard of care is not consistently available to patients in
England. In addition, our systematic literature search con-
ﬁrmed a world-wide knowledge gap with respect to the
safest, most effective referral model/organization of services
for the management of TAD. Neither was identiﬁed the
minimum service speciﬁcation for centers that undertake
interventions on the thoracic aorta.
To our knowledge, this is the ﬁrst nation-wide analysis of
the quantity and quality of care for patients with TAD. The
study used prospectively collected data from 2 large
independent national databases used by the NHS to monitor
quality. These contain data on every patient presenting to
hospital with TAD or undergoing surgery for TAD in English
hospitals. The limitations are those of all registry analyses,
notably the risks of confounding and other sources of bias,
including variable data quality. We attempted to minimize
confounding by adjusting for a large number of baseline
patient-related factors, including demographics, social depri-
vation, comorbidity, and presentation. Detection bias was
mitigated by using objective measures of outcome and
exposures of interest. The NACSA database uses consistent,
well-deﬁned deﬁnitions of exposures and outcomes and
undergoes regular internal and external quality assurance
processes. Being an administrative database, HES is more
likely to have variations in data quality by hospital; under-
recording of comorbidities, for instance, is a well-known
limitation. For the TAD diagnosis date, we used the date of
ﬁrst recording of TAD in 1 of the diagnosis ﬁelds or the date of
the TAD procedure if the patient had no earlier TAD
admission, implying some uncertainty in the actual diagnosis
date. However, certain ﬁelds, such as for the primary
diagnosis and procedure, have been shown to be reliable by
a recent systematic review.68 A further limitation is that it was
not possible to link the HES and NACSA analyses to further
explore potential reasons for variability in care. This is
because the geographical regions served by individual cardiac
centers often overlap. The 2 cohorts also considered different
time periods; this was attributed to the availability of
complete, cleaned HES data to March 2011, and the
availability of data that used consistent deﬁnitions for aortic
Table 4. Mortality Rates by Volume Center Activity (NACSA Cohort)
Frequency
Observed
Mortality (%)
Unadjusted
OR (95% CI)
Adjusted
OR (95% CI)
Activity tertile*
Low-volume (latest 3 years’ activity) 1308 10.6 Reference Reference
Medium-volume (latest 3 years’ activity) 2159 9.5 0.89 (0.71, 1.12) 0.80 (0.62, 1.02)
High-volume (latest 3 years’ activity) 4591 8.8 0.82 (0.67, 1.00) 0.76 (0.60, 0.95)
Activity tertile*
Low-volume (6 years’ activity) 1424 11.1 Reference Reference
Medium-volume (6 years’ activity) 2353 9.5 0.84 (0.68, 1.05) 0.83 (0.66, 1.05)
High-volume (6 years’ activity) 4281 8.6 0.75 (0.62, 0.91) 0.71 (0.57, 0.88)
NACSA indicates National Adult Cardiac Surgery audit; OR, odds ratio.
*Adjusted for preoperative comorbidities, operative risk factors, and most distal aortic segment.
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disease in the NACSA database between 2007 and 2013. Our
analyses did not speciﬁcally consider the role of thoracic
endovascular aortic repair (TEVAR). It has been suggested that
this has important effects on the mortality of aortic disease,
and almost all studies have shown excellent operative
mortality rates post-TEVAR compared to open repair, with
even higher survival rates after emergent aortic proce-
dures.57,69 The total numbers of TEVARs listed in the HES
database to 2011 were small (n=532), however, preventing
useful and detailed analysis.
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Figure 4. Forest plot with unadjusted (top) and adjusted (bottom) risk estimates for in-hospital/30-day mortality in high- versus low-volume
hospitals. OR indicates odds ratio.
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In addition, our analysis did not account for the potential
impact of surgical techniques adopted across English units in
the outcomes of TAD patients undergoing surgery. Rates and
modality of circulatory arrest used during complex TAD
operation, arterial cannulation, and cerebral protection strate-
gies per center were not collected in HES and NACSA
databases. This precluded further analyses and the possibility
to evaluate these surgical strategies as an additional measure
of the quality of care in TAD patients, although arterial
cannulation strategies and cerebral protection strategies have
been proved to inﬂuence operative outcomes in aortic
surgery.70,71
The systematic review was limited in that it relied on the
reported information on confounding variables that were
controlled for; consistent analyses of all studies can be done
only when data on individual patients are combined. Many of
the included studies were at risk of bias, and there was
substantial heterogeneity in many of the effect estimates. We
speculate that this reﬂected differences in the deﬁnitions of
exposures of interest, including the deﬁnition of a high case
volume or what constituted an aortic multidisciplinary team.
For example, the deﬁnition of high versus low volume was
deﬁned, in some studies, as annualized activity versus study
period activity, with the numbers of cases expressed varyingly
as tertiles or medians.**
These limitations notwithstanding, this study has demon-
strated variability in the quality of care for patients with TAD
that appears to be unwarranted. This is a common ﬁnding in
studies of variation in access to care for patients with
cardiovascular disease in England and elsewhere.17,72 Some
of the contributory factors to variation identiﬁed in this report,
such as social deprivation, require complex and difﬁcult
solutions; however, variations in structure and processes of
care are more readily addressed. For example, service
speciﬁcations for the provision of vascular surgery in England
have led to substantive reorganization of care pathways, the
concentration of multidisciplinary expertise in teams, and
signiﬁcant improvements in key markers of quality, such as
mortality following elective aneurysm repair.73,74 In the
current study, higher-volume units and those undertaking
signiﬁcant numbers of more-complex procedures were more
likely to have structures in place that were identiﬁed in the
systematic review as being associated with better outcomes,
speciﬁcally hybrid operating theatres, and adequately
resourced MDT aortic teams. On the basis of these results,
we suggest that these structures should be included in any
future service speciﬁcation for thoracic aortic disease. The
deﬁnition of an adequate unit volume is more difﬁcult; the
NASCA data identiﬁed units in the lowest tertile of total cases
(<32 cases per year) as having a higher mortality, often with a
denominator that included a less-complex caseload. However,
the current study did not speciﬁcally address whether this
reﬂects outcomes following the treatment of emergent
patients. This is important: Patients with acute type A
dissection who do not receive treatment die at a rate of 1%
to 2% per hour during the ﬁrst day and almost half die by
1 week.75 A reduction in the numbers of units providing
emergency services should be balanced by the increase in risk
posed by delays in treatment. However, both HES and NACSA
databases do not account for information regarding the
referral time, interhospital coordination, and transport of
patient affected by TAD, especially in the emergent setting,
and we were unable to investigate this important aspect of
quality of care.56
The results of the NASCA analysis also indicated uncer-
tainty as to whether the volume outcome relationship applied
to all segments of the aorta, although this may be attributable
to a smaller sample size for more-distal segments resulting in
less precision in the estimates. The systematic review did not
indicate that surgeon volume was associated with outcome.
This may also reﬂect the limits of precision when evaluating
small numbers of surgeons, the majority of whom undertake
low numbers of cases. Alternatively, as suggested by the
systematic review, it may be the structures and process
beyond that surgeon that are critical determinants of
outcome.
The present analyses also identiﬁed potential sources of
unwarranted variation that will not be addressed solely by
reconﬁguration of specialist teams, for example, with respect
to differences in treatment rates for aneurysms versus
nonaneurysms, or for emergent versus nonemergent surgery.
We speculate that additional barriers to treatment exist before
hospital treatment. This variation can be addressed by
guidelines for screening, for example, in ﬁrst-degree relatives
of patients with acute aortic syndromes or bicuspid aortic
valves, the use of appropriate imaging, and referral to the TAD
service. However, a barrier to the development of these
processes is the absence of evidence from randomized trials
as to how TAD should be diagnosed and treated. Recent
guidelines were based exclusively on evidence from observa-
tional analyses and expert opinion.20–22
A ﬁnal comment is that the variation in TAD services that
were observed in this study were not apparent when
comparing mortality rates in treated patients by center, the
current methods used by Dr Foster (HES), and the National
Institute for Comparative Outcomes Research (NASCA) for
measuring quality in English cardiac uits.28–30 It is also
noteworthy that there was no evidence from the HES analysis
that cardiac surgery units preferentially select patients that
will have an acceptable outcome following surgery; treatment
rates were not determined by patient mortality risk. This**References: 6–10,13,34–36,50–55,58–63,65.
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refutes a common criticism that the publication of mortality
rates in treated patients, as has occurred in England since
2004, contributes to unwarranted variation.76
In conclusion, evidence of unwarranted variation in the
quality of care supports a reorganization of TAD services in
England, with greater emphasis on care delivered by multidis-
ciplinary teams in specialist centers. Similar service speciﬁca-
tions and recommendations for standards of care and service
delivery for TAD patients have also been commonly observed in
other countries, mainly in North America and Europe. However,
the safest, most effective referral model/organization of
services for the management of TAD has not been identiﬁed.
Further research must focus on the identiﬁcation of barriers to
early diagnosis and referral for treatment, and comparative
trials of treatment options for patients with TAD.
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Supplemental Methods 
 
Data sources and study populations 
Data were extracted from the HES and the NICOR NACSA registry, according to The REporting of studies 
Conducted using Observational Routinely collected health Data (RECORD) statement.1 The need to obtain 
informed consent from patients was waived by the University of Leicester Research Governance Office since 
the identifiable information was either removed or pseudonymized. The study was approved by the NICOR 
NACSA Research Board (study reference 14-ACS-25).  
 
HES cohort  
Hospital Episodes Statistics is the national hospital administrative database for England and covers all 
admissions to public (NHS) hospitals in the country.2 The data contain demographic, administrative and clinical 
information including procedures and operations. The database includes 20 diagnostic fields coded using ICD-
10 and 24 procedure fields coded using the UK’s own OPCS-4 system (Office of Population, Censuses and 
Surveys: Classification of interventions and procedures, 4th Revision). Admissions with a primary or secondary 
diagnosis code of TAD (ICD10 I710, I711, I712, I715, I716) or with a procedure for TAD repair (OPCS codes L181, 
L182, L191, L192, L201, L202, L208, L209, L211, L212, L273, L283, L221) were extracted for the financial years 
2005/6 to 2010/11 inclusive (the most recent for which we had out-of-hospital deaths from the Office for 
National Statistics [ONS] files linked to HES) (Table S1 in the online-only Data Supplement). Using HES’s 
anonymised patient identifier and admission dates, admissions were ordered chronologically by patient, with 
their first one between 2005/6 and 2010/11 flagged. After tracking back five years from this first TAD 
admission (back to 2000/1), patients were excluded if they had had a TAD admission or procedure during these 
five years. The remainder were considered index TAD admissions. We then tracked forward in time from these 
index admissions to capture any TAD procedures (surgery or endovascular procedures) within six months.  
Outcomes of interest were: having an operation (surgical and/or endovascular) either during the index or 
within six months of it; having an elective rather than an emergency operation; post-operative mortality within 
six months; and mortality within six months in patients not having an operation. Death was defined as that in 
or out of hospital within six months of the index admission date.  
For each patient, the postcode sector was mapped to a county via online look-ups between postcode sector 
and local authority and then local authority and county. “County” is actually unitary authority, but many retain 
their county names and we therefore refer to “county” throughout. Some had to be combined due to small 
numbers, finally leaving 40 counties (e.g., the Isle of Wight was merged with Hampshire).  
 
NACSA cohort  
Prospectively collected data for all adult patients undergoing major aortic surgery were extracted from the 
NICOR NACSA registry (version 4.1.2) on 20th November 2014. All surgical procedures included in the study 
were performed in England between the 1st of April 2007 and the 31st of March 2013 and constituted the 
“complete-case” dataset. NICOR manage the audit and receive clinical direction and strategy from the Society 
for Cardiothoracic Surgery in Great Britain and Ireland (SCTS).16 Reproducible cleaning algorithms were applied 
to the database.29,30 Briefly, duplicate records and non-adult cardiac surgery entries were removed, 
transcriptional discrepancies harmonised and clinical and temporal conflicts and extreme values corrected or 
removed. The output from the pre-processing is regularly checked by reporting data summaries back to 
individual units for local validation and inspection as part of the NACSA in the UK.3-7   
For each operation, records on patient characteristics and demographics, comorbidities, intraoperative factors, 
and postoperative outcomes were collected. Administrative data were also extracted including: patient 
admission, procedure and discharge dates and responsible consultant surgeon. For each record, calibrated 
logistic EuroSCORE was calculated.8 Missing data were assumed to be absent for categorical variables or 
replaced with the mean value for continuous variables. Ejection fraction was the categorical variable with the 
highest incidence of missing data (3.5%). The proportions of missing data for continuous variables were: age, 
0%; BMI, 3.6%; cardiopulmonary bypass time, 2.3%; and aortic cross clamp time, 2.9%. The primary outcome 
measure was in-hospital mortality, defined as death in hospital following the index surgical procedure and prior 
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to transfer from the cardiac surgery unit as per the definition used in the national audit. Therefore, records 
were excluded from the analysis if in-hospital mortality status was missing (n=32, 0.4%).   
Operations were divided into four separate categories based on the operated segment most distal to the aortic 
valve included in the procedure, including the aortic root or ascending aorta, aortic arch, descending aorta, and 
the thoracoabdominal aorta. Elective, urgent or emergency procedures were all included. Where operational 
pathology was available, it was divided into three categories: aneurysm, dissection and “other”, the latest 
containing the categories “trauma” and “other”.  
To complement the NACSA study we contacted the Society for Cardiothoracic Surgery Unit Representative for 
every cardiac surgery unit in England and asked 4 questions with respect to the current configuration of TAD 
services in their unit. The questions were: 1. Is there a dedicated Aortic Team? 2. Is there a specific on call rota 
for aortic emergencies? 3. Is there a hybrid operating theatre? 4. Is there a specific aortic multidisciplinary 
team (MDT) meeting recognized in the consultant job plans? Obtained data were cross-referenced with the 
NACSA data on aortic case-volume, complexity and outcomes. Statistical analysis 
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Supplemental Tables 
 
Table S1. The RECORD statement – checklist of items, extended from the STROBE statement 
 
 Item 
No. 
STROBE items and 
Recommendation9 
Location in manuscript 
where items are 
reported (pag.n.) 
RECORD items and 
Recommendation1 
Location in manuscript 
where items are 
reported (pag.n.) 
Title and abstract  
 1 (a) Indicate the study’s design with a 
commonly used term in the title or the 
abstract  
(b) Provide in the abstract an 
informative and balanced summary of 
what was done and what was found 
1,2 
 
 
2 
 
RECORD 1.1: The type of data used should 
be specified in the title or abstract. When 
possible, the name of the databases used 
should be included. 
 
RECORD 1.2: If applicable, the geographic 
region and timeframe within which the 
study took place should be reported in the 
title or abstract. 
 
RECORD 1.3: If linkage between databases 
was conducted for the study, this should be 
clearly stated in the title or abstract. 
1,2 
 
 
 
 
1,2 
 
 
 
 
1,2 
Introduction 
Background 
rationale 
2 Explain the scientific background and 
rationale for the investigation being 
reported 
3  3 
Objectives 3 State specific objectives, including any 
prespecified hypotheses 
3  3 
Methods 
Study Design 4 Present key elements of study design 
early in the paper 
3,4 
Supplemental Material 
  
Setting 5 Describe the setting, locations, and 
relevant dates, including periods of 
recruitment, exposure, follow-up, and 
data collection 
4,5 
Supplemental Material 
  
Participants 6 (a) Cohort study - Give the eligibility 
criteria, and the sources and methods 
 RECORD 6.1: The methods of study 
population selection (such as codes or 
3,4 
Supplemental Material 
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of selection of participants. Describe 
methods of follow-up 
Case-control study - Give the eligibility 
criteria, and the sources and methods 
of case ascertainment and control 
selection. Give the rationale for the 
choice of cases and controls 
Cross-sectional study - Give the 
eligibility criteria, and the sources and 
methods of selection of participants 
 
(b) Cohort study - For matched studies, 
give matching criteria and number of 
exposed and unexposed 
Case-control study - For matched 
studies, give matching criteria and the 
number of controls per case 
algorithms used to identify subjects) should 
be listed in detail. If this is not possible, an 
explanation should be provided.  
 
RECORD 6.2: Any validation studies of the 
codes or algorithms used to select the 
population should be referenced. If 
validation was conducted for this study and 
not published elsewhere, detailed methods 
and results should be provided. 
 
RECORD 6.3: If the study involved linkage of 
databases, consider use of a flow diagram 
or other graphical display to demonstrate 
the data linkage process, including the 
number of individuals with linked data at 
each stage. 
Variables 7 Clearly define all outcomes, 
exposures, predictors, potential 
confounders, and effect modifiers. 
Give diagnostic criteria, if applicable. 
3,4  
Supplemental Material 
RECORD 7.1: A complete list of codes and 
algorithms used to classify exposures, 
outcomes, confounders, and effect 
modifiers should be provided. If these 
cannot be reported, an explanation should 
be provided. 
3,4 
Supplemental Material  
Data sources/ 
measurement 
8 For each variable of interest, give 
sources of data and details of methods 
of assessment (measurement). 
Describe comparability of assessment 
methods if there is more than one 
group 
3,4,  
Supplemental Material  
  
Bias 9 Describe any efforts to address 
potential sources of bias 
Supplemental Material   
Study size 10 Explain how the study size was arrived 
at 
3,4   
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Quantitative 
variables 
11 Explain how quantitative variables 
were handled in the analyses. If 
applicable, describe which groupings 
were chosen, and why 
3,4 
Supplemental Material 
 
  
Statistical methods 12 (a) Describe all statistical methods, 
including those used to control for 
confounding 
(b) Describe any methods used to 
examine subgroups and interactions 
(c) Explain how missing data were 
addressed 
(d) Cohort study - If applicable, explain 
how loss to follow-up was addressed 
Case-control study - If applicable, 
explain how matching of cases and 
controls was addressed 
Cross-sectional study - If applicable, 
describe analytical methods taking 
account of sampling strategy 
(e) Describe any sensitivity analyses 
5,6 
Supplemental Material 
   
Data access and 
cleaning methods 
 ..  RECORD 12.1: Authors should describe the 
extent to which the investigators had access 
to the database population used to create 
the study population. 
 
RECORD 12.2: Authors should provide 
information on the data cleaning methods 
used in the study. 
3-6 
Supplemental Material 
Linkage  ..  RECORD 12.3: State whether the study 
included person-level, institutional-level, or 
other data linkage across two or more 
databases. The methods of linkage and 
methods of linkage quality evaluation 
should be provided. 
3,4 
Supplemental Material 
Results 
Participants 13 (a) Report the numbers of individuals 8-11 RECORD 13.1: Describe in detail the 8-11 
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at each stage of the study (e.g., 
numbers potentially eligible, examined 
for eligibility, confirmed eligible, 
included in the study, completing 
follow-up, and analysed) 
(b) Give reasons for non-participation 
at each stage. 
(c) Consider use of a flow diagram 
selection of the persons included in the 
study (i.e., study population selection) 
including filtering based on data quality, 
data availability and linkage. The selection 
of included persons can be described in the 
text and/or by means of the study flow 
diagram. 
Descriptive data 14 (a) Give characteristics of study 
participants (e.g., demographic, 
clinical, social) and information on 
exposures and potential confounders 
(b) Indicate the number of participants 
with missing data for each variable of 
interest 
(c) Cohort study - summarise follow-up 
time (e.g., average and total amount) 
8-11   
Outcome data 15 Cohort study - Report numbers of 
outcome events or summary 
measures over time 
Case-control study - Report numbers 
in each exposure category, or 
summary measures of exposure 
Cross-sectional study - Report 
numbers of outcome events or 
summary measures 
8-11   
Main results 16 (a) Give unadjusted estimates and, if 
applicable, confounder-adjusted 
estimates and their precision (e.g., 
95% confidence interval). Make clear 
which confounders were adjusted for 
and why they were included 
(b) Report category boundaries when 
continuous variables were categorized 
(c) If relevant, consider translating 
estimates of relative risk into absolute 
risk for a meaningful time period 
8-11   
Other analyses 17 Report other analyses done—e.g., 8-11   
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analyses of subgroups and 
interactions, and sensitivity analyses 
Supplemental Material 
Discussion 
Key results 18 Summarise key results with reference 
to study objectives 
12,13   
Limitations 19 Discuss limitations of the study, taking 
into account sources of potential bias 
or imprecision. Discuss both direction 
and magnitude of any potential bias 
13-15 RECORD 19.1: Discuss the implications of 
using data that were not created or 
collected to answer the specific research 
question(s). Include discussion of 
misclassification bias, unmeasured 
confounding, missing data, and changing 
eligibility over time, as they pertain to the 
study being reported. 
13-15 
Interpretation 20 Give a cautious overall interpretation 
of results considering objectives, 
limitations, multiplicity of analyses, 
results from similar studies, and other 
relevant evidence 
12,16   
Generalisability 21 Discuss the generalisability (external 
validity) of the study results 
16   
Other Information 
Funding 22 Give the source of funding and the 
role of the funders for the present 
study and, if applicable, for the 
original study on which the present 
article is based 
17   
Accessibility of 
protocol, raw data, 
and programming 
code 
   RECORD 22.1: Authors should provide 
information on how to access any 
supplemental information such as the study 
protocol, raw data, or programming code. 
Supplemental Material 
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Table S2. MOOSE Checklist for Meta-analyses of Observational Studies10  
Item N. Recommendation Reported on Page N. 
Reporting of background should include 
1 Problem definition 3  
2 Hypothesis statement 3   
3 Description of study outcome(s) 4,5, tab S5  
4 Type of exposure or intervention used 5, tab S5 
5 Type of study designs used 4,5 
6 Study population 5 
Reporting of search strategy should include 
7 Qualifications of searchers (eg, librarians and investigators) 4,5 
8 Search strategy, including time period included in the synthesis and key words 4,5 
9 Effort to include all available studies, including contact with authors Ref.#32 
10 Databases and registries searched 5 Ref.#32 
11 Search software used, name and version, including special features used (eg, explosion) Ref.#32 
12 Use of hand searching (eg, reference lists of obtained articles) Ref.#32 
13 List of citations located and those excluded, including justification fig S4 Ref.#32 
14 Method of addressing articles published in languages other than English Ref.#32 
15 Method of handling abstracts and unpublished studies Ref.#32 
16 Description of any contact with authors Ref.#32 
Reporting of methods should include 
17 Description of relevance or appropriateness of studies assembled for assessing the hypothesis to be tested Ref.#32 
18 Rationale for the selection and coding of data (eg, sound clinical principles or convenience) Ref.#32 
19 Documentation of how data were classified and coded (eg, multiple raters, blinding and interrater reliability) Ref.#32 
20 Assessment of confounding (eg, comparability of cases and controls in studies where appropriate) Ref.#32 
21 Assessment of study quality, including blinding of quality assessors, stratification or regression on possible predictors of study results 
5 
Ref.#32 
22 Assessment of heterogeneity Supplement 
23 
Description of statistical methods (eg, complete description of fixed or random 
effects models, justification of whether the chosen models account for predictors of 
study results, dose-response models, or cumulative meta-analysis) in sufficient detail 
to be replicated 
Supplement 
24 Provision of appropriate tables and graphics Supplement 
Reporting of results should include 
25 Graphic summarizing individual study estimates and overall estimate fig 4 
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fig S9-13 
26 Table giving descriptive information for each study included tab S11-13 
27 Results of sensitivity testing (eg, subgroup analysis) 11,12 
28 Indication of statistical uncertainty of findings 11,12 
Reporting of discussion should include 
29 Quantitative assessment of bias (eg, publication bias) Supplement 
30 Justification for exclusion (eg, exclusion of non-English language citations) Ref.#32 
31 Assessment of quality of included studies tab S14 
Reporting of conclusions should include 
32 Consideration of alternative explanations for observed results 13,14 
33 Generalization of the conclusions (ie, appropriate for the data presented and within the domain of the literature review) 16 
34 Guidelines for future research 16 
35 Disclosure of funding source 17,18 
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Table S3. PRISMA checklist of Items to Include when Reporting a Systematic Review or Meta-analysis11 
 
Section/topic  # Checklist Item  Reported on Page #  
TITLE  
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT  
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of 
key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  tab V 
METHODS  
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
4,5 
Ref.#32 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
4,5  
tab S5 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
4,5 
Ref.#32 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  5 
Ref.#32 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in 
the meta-analysis).  
2 
Ref.#32 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
5  
Ref.#32 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made.  Ref.#32 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in any data synthesis.  Ref.#32 
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Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  Supplement 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) 
for each meta-analysis.  Supplement  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting 
within studies).  Supplement  
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which 
were pre-specified.  Supplement  
RESULTS  
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each 
stage, ideally with a flow diagram.  11,12 
Study characteristics  18 For each study, present characteristics for which data were extracted and provide the citations.  tab S11-13 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  
tab S14 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group 
(b) effect estimates and confidence intervals, ideally with a forest plot.  
fig 4 
tab S12-13 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  fig 4 
fig S9-13 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  tab S14-15 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  Supplement 
DISCUSSION  
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key 
groups (e.g., healthcare providers, users, and policy makers).  13 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  14-16 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  16 
FUNDING  
Funding 
27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review. 17,18 
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Table S4. List of ICD-10 codes for the comorbidities used in the HES analysis 
 
Code Description 
I10-I15 
Hypertensive 
diseases 
I10 Essential (primary) hypertension  
I11 Hypertensive heart disease  
I12 Hypertensive renal disease  
I13 Hypertensive heart and renal disease  
I15 Secondary hypertension 
I20-I25 Ischaemic 
heart diseases 
I20 Angina pectoris  
I21 Acute myocardial infarction  
I22 Subsequent myocardial infarction  
I23 Certain current complications following acute myocardial infarction  
I24 Other acute ischaemic heart diseases  
I25 Chronic ischaemic heart disease 
I30-I52 Other 
forms of heart 
disease 
I34 Nonrheumatic mitral valve disorders  
I35 Nonrheumatic aortic valve disorders  
I36 Nonrheumatic tricuspid valve disorders  
I37 Pulmonary valve disorders 
I60-I69 
Cerebrovascular 
diseases 
I60 Subarachnoid haemorrhage  
I61 Intracerebral haemorrhage  
I62 Other nontraumatic intracranial haemorrhage 
I63 Cerebral infarction  
I63.0 Cerebral infarction due to thrombosis of precerebral arteries  
I63.1 Cerebral infarction due to embolism of precerebral arteries  
I63.2 Cerebral infarction due to unspecified occlusion or stenosis of precerebral 
arteries  
I63.3 Cerebral infarction due to thrombosis of cerebral arteries  
I63.4 Cerebral infarction due to embolism of cerebral arteries  
I63.5 Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries  
I63.6 Cerebral infarction due to cerebral venous thrombosis, nonpyogenic  
I63.8 Other cerebral infarction  
I63.9 Cerebral infarction, unspecified 
 I64 Stroke, not specified as haemorrhage or infarction  
I65 Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction  
I66 Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction  
I67 Other cerebrovascular diseases  
I68 Cerebrovascular disorders in diseases classified elsewhere  
I69 Sequelae of cerebrovascular disease  
I70 
Atherosclerosis 
I70.0 Atherosclerosis of aorta  
I70.1 Atherosclerosis of renal artery  
I70.2 Atherosclerosis of arteries of extremities  
I70.8 Atherosclerosis of other arteries  
I70.9 Generalized and unspecified atherosclerosis 
I71 Aortic 
Aneurysms not 
affecting the 
thoracic aorta 
I71.3 Abdominal aortic aneurysm, ruptured  
I71.4 Abdominal aortic aneurysm, without mention of rupture  
I71.8 Aortic aneurysm of unspecified site, ruptured  
I71.9 Aortic aneurysm of unspecified site, without mention of rupture 
I72 Other 
aneurysm and 
dissection 
(not affecting the 
thoracic aorta) 
I72.0 Aneurysm and dissection of carotid artery  
I72.1 Aneurysm and dissection of artery of upper extremity  
I72.2 Aneurysm and dissection of renal artery  
I72.3 Aneurysm and dissection of iliac artery  
I72.4 Aneurysm and dissection of artery of lower extremity  
I72.5 Aneurysm and dissection of other precerebral arteries  
I72.8 Aneurysm and dissection of other specified arteries  
I72.9 Aneurysm and dissection of unspecified site 
I73 Other 
peripheral 
vascular diseases 
I73.0 Raynaud syndrome  
I73.1 Thromboangiitis obliterans [Buerger]  
I73.8 Other specified peripheral vascular diseases  
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I73.9 Peripheral vascular disease, unspecified 
I77 Other 
disorders of 
arteries and 
arterioles 
 I77.6 Arteritis, unspecified  
   
I77.8 Other specified disorders of arteries and arterioles  
I77.2 Rupture of artery 
 
I79 Disorders of 
arteries, arterioles 
and capillaries in 
diseases classified 
elsewhere 
I79.0 Aneurysm of aorta in diseases classified elsewhere  
I79.1 Aortitis in diseases classified elsewhere  
I79.2 Peripheral angiopathy in diseases classified elsewhere  
I79.8 Other disorders of arteries, arterioles and capillaries in diseases classified 
elsewhere 
Q20-Q28 
Congenital 
malformations of 
the circulatory 
system 
Q20 Congenital malformations of cardiac chambers and connections  
Q21 Congenital malformations of cardiac septa  
Q22 Congenital malformations of pulmonary and tricuspid valves  
Q23 Congenital malformations of aortic and mitral valves  
Q24 Other congenital malformations of heart  
Q25 Congenital malformations of great arteries  
Q26 Congenital malformations of great veins  
Q27 Other congenital malformations of peripheral vascular system  
Q28 Other congenital malformations of circulatory system 
Q79.6 Ehlers-
Danlos syndrome 
 
Q87 Other 
specified 
congenital 
malformation 
syndromes 
affecting multiple 
systems    
Q87.4 Marfan syndrome  
Q87.5 Other congenital malformation syndromes with other skeletal changes  
Q87.8 Other specified congenital malformation syndromes, not elsewhere classified 
J40-J44 Chronic 
obstructive 
pulmonary 
disease   
J40 Bronchitis, not specified as acute or chronic 
J41 Simple and mucopurulent chronic bronchitis 
J42 Unspecified chronic bronchitis 
J43 Emphysema 
J44 Other chronic obstructive pulmonary disease 
E10-E14 Diabetes 
mellitus 
E10 Insulin-dependent diabetes mellitus 
E11 Non-insulin-dependent diabetes mellitus 
E12 Malnutrition-related diabetes mellitus 
E13 Other specified diabetes mellitus 
E14 Unspecified diabetes mellitus 
E66 Obesity  
E78 Disorders of 
lipoprotein 
metabolism and 
other lipidaemias 
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Table S5. PICOS criteria for inclusion and exclusion of studies into meta-analysis 
 
Parameter Inclusion criteria Exclusion criteria 
Patients Adult patients affected by TAD Patients affected by other cardiac diseases other than TAD  
Intervention* Open surgery or endovascular repair of TAD   Study without definition of volume activity 
Comparator Hospital volume activity  - 
Outcomes 
Primary: in-hospital/30-day mortality (all cause) 
Secondary: postoperative stroke; re-exploration for 
bleeding/tamponade; postoperative renal failure; length of 
hospitalization 
Late mortality 
Study design 
Clinical randomised trials 
Controlled before-and-after studies 
Prospective and retrospective cohort studies 
Cross-sectional studies 
Case-control studies 
Repeat publications of the same analysis or dataset 
Conference abstracts 
Editorials & opinion pieces 
Books or grey literature 
 
Abbreviations: TAD, thoracic aortic disease. 
 
* Main intervention/comparator; other intervention/comparator: surgeon volume (high- vs. low-volume); teaching hospital status (teaching vs. non-teaching); urban 
hospital status (urban vs. rural); aortic dedicated team presence (aortic team vs. no-aortic team); dedicated thoracic aortic surgery program (program vs. no program; 
presence of cardiothoracic unit along with hybrid room. 
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Table S6. Risk factors for patients affected by thoracic aortic disease who received treatment and for 
patients who received non-emergent rather than emergent treatment (HES cohort) 
 
Factor 
 Receiving treatment  Receiving non-emergent 
rather than emergency 
treatment 
 
 Value OR (95% CI) P-value OR (95% CI) P-value 
Age 0-39 2.15 (1.82 to 2.53) <.0001 0.68 (0.50 to 0.91) 0.01 
 40-44 1.55 (1.27 to 1.90) <.0001 1.12 (0.77 to 1.64) 0.5504 
 45-49 1.36 (1.13 to 1.64) 0.0012 0.98 (0.68 to 1.40) 0.9022 
 50-54 1.32 (1.12 to 1.56) 0.0011 0.98 (0.71 to 1.34) 0.8743 
 55-59 1.35 (1.17 to 1.56) <.0001 0.88 (0.67 to 1.16) 0.3626 
 60-64 1.16 (1.01 to 1.32) 0.0315 0.87 (0.67 to 1.12) 0.2699 
 65-69 1  1  
 70-74 0.84 (0.75 to 0.95) 0.0041 0.88 (0.70 to 1.10) 0.2626 
 75-79 0.61 (0.54 to 0.69) <.0001 0.85 (0.67 to 1.07) 0.1621 
 80-84 0.29 (0.25 to 0.33) <.0001 0.52 (0.39 to 0.68) <.0001 
 85-89 0.11 (0.09 to 0.14) <.0001 0.29 (0.18 to 0.46) <.0001 
 90+ 0.02 (0.01 to 0.04) <.0001 0.37 (0.09 to 1.45) 0.1516 
Sex Female 1.04 (0.97 to 1.12) 0.2385 1.00 (0.87 to 1.15) 0.9975 
 Male 1  1  
Year 2004 1.24 (1.09 to 1.40) 0.0009 0.88 (0.69 to 1.13) 0.3185 
Year 2005 1.30 (1.15 to 1.47) <.0001 0.84 (0.66 to 1.06) 0.1313 
Year 2006 1.36 (1.20 to 1.53) <.0001 0.75 (0.60 to 0.94) 0.0131 
Year 2007 1.21 (1.07 to 1.35) 0.0014 0.83 (0.66 to 1.04) 0.1012 
Year 2008 1.01 (0.90 to 1.13) 0.8694 0.97 (0.77 to 1.21) 0.7698 
Year 2009 0.98 (0.87 to 1.09) 0.6823 0.93 (0.74 to 1.16) 0.5082 
Year 2010 1  1  
Deprivation 1 (least 
deprived) 
1  1  
Deprivation 2 0.95 (0.86 to 1.04) 0.2541 1.05 (0.87 to 1.26) 0.6245 
Deprivation 3 0.88 (0.79 to 0.97) 0.0093 0.74 (0.61 to 0.90) 0.0021 
Deprivation 4 0.82 (0.73 to 0.91) 0.0001 0.83 (0.68 to 1.01) 0.0605 
Deprivation 5 (most 
deprived) 
0.69 (0.62 to 0.78) <.0001 0.61 (0.49 to 0.76) <.0001 
Atherosclerosis  1.45 (1.24 to 1.68) <.0001 0.98 (0.74 to 1.29) 0.8616 
Cancer  0.70 (0.62 to 0.80) <.0001 1.25 (0.97 to 1.60) 0.0847 
Congenital 
malformation 
circulatory 
disorders 
 1.17 (1.03 to 1.34) 0.0182 1.82 (1.43 to 2.31) <.0001 
COPD  0.64 (0.57 to 0.71) <.0001 0.79 (0.63 to 0.98) 0.0332 
Cerebrovascular 
disease 
 0.83 (0.73 to 0.94) 0.0025 0.86 (0.67 to 1.11) 0.2421 
Diabetes  0.82 (0.73 to 0.93) 0.0019 1.02 (0.80 to 1.30) 0.8775 
Hypertension  1.04 (0.97 to 1.12) 0.3026 1.15 (1.00 to 1.33) 0.0444 
Ischaemic heart 
disease 
 0.84 (0.78 to 0.91) <.0001 1.38 (1.20 to 1.60) <.0001 
Lipid disorders  1.06 (0.97 to 1.15) 0.1928 1.57 (1.33 to 1.84) <.0001 
Other aneurysm  1.07 (0.86 to 1.34) 0.5549 0.86 (0.58 to 1.28) 0.4506 
Other aortic 
disease 
 2.42 (2.24 to 2.63) <.0001 1.32 (1.15 to 1.53) 0.0001 
Disorders of 
other arteries 
 2.04 (1.05 to 2.77) <.0001 0.30 (0.18 to 0.49) <.0001 
Other congenital 
malformation 
 0.90 (0.72 to 1.12) 0.3464 3.17 (2.04 to 4.91) <.0001 
Other IHD  1.41 (1.31 to 1.51) <.0001 1.52 (1.33 to 1.74) <.0001 
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Other PVD  0.90 (0.78 to 1.05) 0.1857 0.85 (0.64 to 1.14) 0.2802 
Renal disease  0.58 (0.50 to 0.68) <.0001 0.74 (0.55 to 1.00) 0.0466 
Dissection  0.71 (0.66 to 0.77) <.0001 0.06 (0.05 to 0.08) <.0001 
 
Abbreviations: CI, confidence interval; COPD, chronic pulmonary disease; HES, hospital episodes statistics; IHD, 
ischemic heart disease; OR, odds ratio; PVD, peripheral vascular disease. 
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Table S7. Risk factors for 6-month mortality in patients receiving treatment for thoracic aortic disease and in 
those not receiving any thoracic aortic treatment (HES cohort) 
 
Factor  Mortality in those 
receiving treatment 
 Mortality in those 
not receiving 
treatment 
 
Value OR (95% CI) p value OR (95% CI) p value 
Age 0-39 0.75 (0.51 to 1.10) 0.1407 0.45 (0.33 to 0.61) <.0001 
Age 40-44 0.37 (0.20 to 0.67) 0.0011 0.70 (0.50 to 0.98) 0.0351 
Age 45-49 0.41 (0.24 to 0.71) 0.0014 0.49 (0.35 to 0.67) <.0001 
Age 50-54 0.60 (0.39 to 0.93) 0.0211 0.57 (0.43 to 0.75) <.0001 
Age 55-59 0.77 (0.55 to 1.08) 0.1307 0.72 (0.58 to 0.90) 0.0039 
Age 60-64 0.93 (0.69 to 1.26) 0.6272 0.89 (0.74 to 1.08) 0.2349 
Age 65-69 1  1  
Age 70-74 1.12 (0.85 to 1.46) 0.4236 1.32 (1.14 to 1.54) 0.0003 
Age 75-79 1.35 (1.03 to 1.77) 0.0272 1.66 (1.44 to 1.92) <.0001 
Age 80-84 1.57 (1.14 to 2.16) 0.0057 2.03 (1.77 to 2.34) <.0001 
Age 85+ 2.72 (1.71 to 4.32) <.0001 2.85 (2.47 to 3.28) <.0001 
sex Female 0.96 (0.81 to 1.13) 0.6129 0.79 (0.74 to 0.85) <.0001 
sex Male 1  1  
Year 2004 1.38 (1.02 to 1.85) 0.0343 1.70 (1.50 to 1.94) <.0001 
Year 2005 1.84 (1.39 to 2.44) <.0001 1.65 (1.46 to 1.88) <.0001 
Year 2006 1.20 (0.90 to 1.59) 0.2115 1.40 (1.23 to 1.58) <.0001 
Year 2007 1.20 (0.91 to 1.58) 0.2048 1.21 (1.07 to 1.37) 0.0021 
Year 2008 1.16 (0.87 to 1.53) 0.3118 1.13 (1.00 to 1.27) 0.0445 
Year 2009 0.97 (0.73 to 1.29) 0.8283 1.03 (0.92 to 1.16) 0.5994 
Year 2010 1  1  
Elective adm No 0.29 (0.24 to 0.34) <.0001 0.26 (0.23 to 0.28) <.0001 
Elective adm Yes 1  1  
Deprivation 1 (least 
deprived) 
1  1  
Deprivation 2 1.11 (0.88 to 1.40) 0.3893 1.02 (0.91 to 1.14) 0.7717 
Deprivation 3 1.18 (0.94 to 1.50) 0.1581 1.12 (1.00 to 1.25) 0.0413 
Deprivation 4 1.20 (0.94 to 1.53) 0.1517 1.18 (1.05 to 1.32) 0.0047 
Deprivation 5 (most 
deprived) 
1.13 (0.86 to 1.49) 0.3757 1.11 (0.98 to 1.25) 0.0877 
Atherosclerosis  1.73 (1.27 to 2.35) 0.0005 1.17 (0.99 to 1.38) 0.0658 
Cancer  1.72 (1.31 to 2.27) 0.0001 1.65 (1.49 to 1.83) <.0001 
Congenital 
malformation 
circulatory 
disorders  
 0.88 (0.62 to 1.24) 0.4621 0.70 (0.51 to 0.94) 0.0188 
COPD  1.37 (1.07 to 1.74) 0.0126 1.28 (1.17 to 1.40) <.0001 
Cerebrovascular 
disease 
 1.92 (1.50 to 2.46) <.0001 1.25 (1.13 to 1.39) <.0001 
Diabetes  1.25 (0.95 to 1.65) 0.1103 1.06 (0.94 to 1.18) 0.3545 
Hypertension  0.85 (0.71 to 1.00) 0.0508 0.93 (0.86 to 1.00) 0.0557 
Ischaemic heart 
disease 
 1.45 (1.22 to 1.72) <.0001 0.81 (0.75 to 0.87) <.0001 
Lipid disorders  0.77 (0.63 to 0.94) 0.0092 0.73 (0.66 to 0.80) <.0001 
Other aneurysm  1.05 (0.65 to 1.70) 0.8285 1.09 (0.85 to 1.39) 0.5058 
Other aortic 
disease 
 1.17 (0.97 to 1.40) 0.0969 1.18 (1.07 to 1.29) 0.0008 
Disorders of 
other arteries 
 0.92 (0.52 to 1.64) 0.7854 1.02 (0.68 to 1.53) 0.9235 
Other congenital 
malformation 
 0.71 (0.38 to 1.34) 0.2933 0.68 (0.43 to 1.07) 0.096 
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Other IHD  1.00 (0.85 to 1.18) 0.9932 1.15 (1.07 to 1.23) 0.0002 
Other PVD  1.28 (0.93 to 1.78) 0.1332 1.44 (1.25 to 1.66) <.0001 
Renal disease  2.11 (1.56 to 2.85) <.0001 1.55 (1.38 to 1.73) <.0001 
Dissection  1.07 (0.88 to 1.30) 0.509 1.83 (1.69 to 1.98) <.0001 
 
Abbreviations: Adm, admission; CI, confidence interval; COPD, chronic pulmonary disease; HES, hospital 
episodes statistics; IHD, ischemic heart disease; OR, odds ratio; PVD, peripheral vascular disease. 
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Table S8. Baseline, operative and mortality details by most distal aortic segment (NACSA cohort)  
 
Variables* Root/Ascending Aorta (n = 6848) 
Aortic Arch 
(n = 762) 
Descending Aorta 
(n = 320) 
Thoracoabdominal 
(n = 128) 
Demographics 
  Age at operation (years) 64 (51, 73) 68 (57, 74) 62 (45, 71) 63 (48, 70) 
  BMI (kg/m2) 26.9 (24.1, 30.1) 26.5 (23.8, 29.8) 26.1 (23.4, 29.3) 25.0 (21.8, 28.3) 
  Female gender 2216 (32.4) 308 (40.4) 117 (36.6) 50 (39.1) 
Co-morbidities 
  Unstable angina 332 (4.9) 29 (3.8) 7 (2.2) 4 (3.1) 
  NYHA ≥ III class 2075 (30.3) 165 (21.7) 58 (18.1) 18 (14.1) 
  MI within 90 days of operation 246 (3.6) 15 (2.0) 0 (0) 7 (5.5) 
  Previous cardiac surgery 984 (14.4) 121 (15.9) 113 (35.3) 34 (26.6) 
  Previous aortic surgery 199 (2.9) 59 (7.7) 60 (18.8) 17 (13.3) 
  Diabetes 487 (7.1) 44 (5.8) 14 (4.4) 8 (6.3) 
  Current smoker 749 (10.9) 90 (11.8) 46 (14.4) 22 (17.2) 
  Hypertension 4148 (60.6) 569 (74.7) 231 (72.2) 88 (68.8) 
  Creatinine > 200 (μmol/l) 190 (2.8) 22 (2.9) 7 (2.2) 5 (3.9) 
  History of renal dysfunction 106 (1.6) 19 (2.5) 6 (1.9) 3 (2.3) 
  History of pulmonary disease 783 (11.4) 111 (14.6) 47 (14.7) 33 (25.8) 
  History of stroke 558 (8.2) 80 (10.5) 19 (5.9) 4 (3.1) 
  Neurological dysfunction 252 (3.7) 38 (5.0) 14 (4.4) 2 (1.6) 
  Peripheral vascular disease 909 (13.3) 242 (31.8) 104 (32.5) 57 (44.5) 
  Non sinus cardiac rhythm 828 (12.1) 85 (11.2) 19 (5.9) 6 (4.7) 
  Triple vessel disease 318 (4.6) 35 (4.6) 6 (1.9) 12 (9.4) 
  Left main stem disease 138 (2.0) 8 (1.1) 2 (0.6) 4 (3.1) 
  Moderate LVEF (30-50%) 1418 (20.7 125 (16.4) 29 (9.1) 12 (9.4) 
  Poor LVEF (<30%) 308 (4.5) 17 (2.2) 3 (0.9) 0 (0) 
  PA systolic > 60mmHg 90 (1.3) 4 (0.5) 0 (0) 0 (0) 
  Pre-operative IV nitrates 324 (4.7) 60 (7.9) 19 (5.9) 8 (6.3) 
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  Pre-operative IV inotropes 187 (2.7) 15 (2.0) 18 (5.6) 6 (4.7) 
  Pre-operative ventilation 138 (2.0) 15 (2.0) 13 (4.1) 0 (0) 
  Pre-operative cardiogenic shock 306 (4.5) 24 (3.2) 10 (3.1) 2 (1.6) 
Operative details  
  Non-elective priority 2438 (35.6) 317 (41.6) 141 (44.1) 45 (35.2) 
      Urgent priority 1076 (15.7) 127 (16.7) 64 (20.0) 28 (21.9) 
      Emergency priority 1249 (18.2) 177 (23.2) 68 (21.3) 16 (12.5) 
      Salvage priority 113 (1.7) 13 (1.7) 9 (2.8) 1 (0.8) 
  Concomitant CABG operation 1334 (19.5) 122 (16.0) 12 (3.8) 14 (10.9) 
  Concomitant valve operation 4963 (72.5) 326 (42.8) 24 (7.5) 6 (4.7) 
  Concomitant 'other' operation 2320 (33.9) 188 (24.7) 99 (30.9) 39 (30.5) 
  Dominant pathology     
      Aneurysm 3800 (55.5) 410 (53.8) 138 (43.1) 74 (57.8) 
      Dissection 1410 (20.6) 269 (35.3) 93 (29.1) 47 (36.7) 
      Trauma 27 (0.4) 4 (0.5) 19 (5.9) 0 (0) 
      'Other' 1113 (16.3) 58 (7.6) 58 (18.1) 5 (3.9) 
      Data N/A 498 (7.3) 21 (2.8) 12 (3.8) 2 (1.6) 
  CPB time (minutes) 157 (116, 216) 205 (152, 266) 184 (78, 260) 164 (110, 227) 
  ACC time (minutes) 107 (79, 142) 112 (70, 156) 42 (0, 100) 27 (0, 117) 
  Circulatory arrest time (minutes) 25 (18, 33) 28 (18, 46) 36 (28, 57) 27 (15, 42) 
Outcome 
  In-hospital mortality 569 (8.3) 101 (13.3) 49 (15.3) 29 (22.7) 
 
Abbreviations: ACC, aortic cross clamp time; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; LVEF, left ventricle ejection fraction; N/A, not available; 
NACSA, National Adult Cardiac Surgery Audit; NYHA, New York Heart Association; PA, pulmonary artery. 
 
*Numerical data are expressed as median and interquartile range (IQR); categorical data as absolute number (percentage). 
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Table S9. Hospital volume tertiles by most distal aortic segment (calculated by mean 3 year annual activity) 
(NACSA cohort)  
 
Tertiles of activity* 
Low volume  Medium volume High volume  
(n = 1308) (n = 2159) (n = 4591) 
Category range for all aortic surgery 0 to 31 operations 32 to 52 operations 53 or more operations 
  Root / Ascending Aorta 1211 (92.6) 1798 (83.3) 3839 (83.6) 
  Aortic Arch 75 (5.7) 275 (12.7) 412 (9.0) 
  Descending Aorta 17 (1.3) 58 (2.7) 245 (5.3) 
  Thorocoabdominal Aorta 5 (0.4) 28 (1.3) 95 (2.1) 
Half (median) of activity 
Lower half activity Upper half activity 
(n = 2254) (n = 5804) 
Category range for all aortic surgery 0 to 38 operations 39 or more operations 
  Root / Ascending aorta 1964 (87.1) 4884 (84.2) 
  Aortic Arch 214 (9.5) 548 (9.4) 
  Descending Thoracic Aorta 44 (2.0) 276 (4.8) 
  Thorocoabdominal Aorta 32 (1.4) 96 (1.7) 
 
Abbreviations: NACSA, National Adult Cardiac Surgery Audit. 
 
*Data are expressed in absolute numbers (percentage). 
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Tables S10. Unadjusted and adjusted in-hospital mortality rates by aortic procedure and hospital volume 
(NACSA cohort)* 
 
 Low volume Medium volume High volume 
Root / Ascending Aorta    
   Observed mortality rate (%) 10.7 8.3 7.4 
   Unadjusted odds ratio (95% CI) Reference 0.76 (0.60, 0.96) 0.67 (0.54, 0.83) 
   Adjusted odds ratio (95% CI) Reference 0.75 (0.57, 0.98) 0.65 (0.51, 0.83) 
Aortic Arch    
   Observed mortality rate (%) 13.1 13.2 13.4 
   Unadjusted odds ratio (95% CI) Reference 1.01 (0.52, 1.97) 1.02 (0.54, 1.93) 
   Adjusted odds ratio (95% CI) Reference 1.28 (0.61, 2.65) 1.27 (0.63, 2.55) 
Descending Aorta    
   Observed mortality rate(%) 20.0 28.1 11.8 
   Unadjusted odds ratio (95% CI) Reference 1.56 (0.50, 4.87) 0.53 (0.19, 1.53) 
   Adjusted odds ratio (95% CI) Reference 2.36 (0.64, 8.76) 0.75 (0.23, 2.48) 
Thorocoabdominal Aorta    
   Observed mortality rate (%) 14.3 28.6 22.6 
   Unadjusted odds ratio (95% CI) Reference 2.40 (0.41, 14.11) 1.75 (0.36, 8.44) 
   Adjusted odds ratio (95% CI) Reference 2.28 (0.35, 14.65) 2.19 (0.42, 11.50) 
 
Abbreviations: CI, confidence interval; NACSA, National Adult Cardiac Surgery Audit.  
 
*Hospital volume was calculated by mean of the last 3 year annual activity and subdivided for tertiles of 
activity.  
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Table S11. Characteristics of the studies included in the systematic review 
 
Study 
(Author, Year) 
Design Country 
(Source)* 
Sample 
size 
Study 
period 
Inclusion criteria Exclusion 
criteria 
Outcomes Aortic centre 
configuration 
Hospital 
Volume 
Threshold 
(cases/yr) 
Shaffer et al,12 
2015 
Retrospective 
cohort study, 
Multicenter 
USA 
(MEDPAR) 
5578 1999-2010 Open descending 
thoracic aorta and 
thoracoabdominal 
repair 
 Postoperative 
survival 
No LV:<50† 
MV: 50-200 
HV:>200 
Shaffer et al,13 
2015 
Retrospective 
cohort study, 
Multicenter 
USA 
(MEDPAR) 
11996 2005-2010 TEVAR  Postoperative 
survival 
No LV:<20† 
MV: 20-99 
HV:≥100 
 
Bhatt et al,14 
2015 
Retrospective 
cohort study, 
Multicenter 
USA 
(NIS) 
105 2000-2011 TEVAR in adult 
aortic coarctation  
 Vascular 
complications 
(vascular injury, 
hemorrhage 
requiring transfusion, 
aortic dissection, 
arteriovenous fistula, 
accidental puncture, 
other vascular 
complications), any 
cardiac 
complications, open 
vascular/cardiac 
surgery, stroke/TIA, 
any respiratory 
complications, 
PE/DVT, anaesthetic 
complications, 
infection 
NO LV:<3 
HV:≥3 
Brat et al,15  
2015 
Retrospective 
cohort study, 
Monocenter 
Czech 
Republic 
(Inst.Dat.) 
30 1999-2013 Elective aortic 
arch aneurysm 
Acute 
operation and 
aortic 
dissection  
30-day/in-hospital 
mortality, postop 
complications 
(permanent/transient 
neurological deficit, 
No NA 
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haemodialysis, 
reoperation for 
bleeding, 
postoperative blood 
loss, intubation), LOS  
Grau et al,16 
2015 
Retrospective 
case 
controlled,  
Monocenter 
USA 
(Inst.Dat.) 
54 2002-2013 Acute type A 
aortic dissection 
 In-hospital mortality, 
postop complications 
(cardiac arrest, 
stroke, ARF, 
reoperation for 
bleeding, AF, 
prolonged 
intubation), LOS, 
Yes NA 
Lenos et al,17 
2015 
Retrospective 
cohort study,  
Monocenter 
Germany 
(Inst.Dat.) 
162 2002-2013 Acute type A 
aortic dissection 
 30-day/in-hospital 
mortality, 90-day 
mortality, new 
permanent 
neurological deficit, 
adverse outcome 
No NA 
Iribarne et al,18  
2015 
Retrospective 
cohort study, 
Multicenter 
USA  
(NIS) 
1230 2005-2008 Acute aortic 
dissection 
Non-emergent 
pts, pts<18 yr, 
TEVAR 
In-hospital mortality, 
postop complications 
(AMI, stroke, ARF, 
pneumonia, 
septicaemia), LOS, 
discharge disposition, 
hospitalization costs 
No LV: ≤ 5 
MV: 6-10 
HV: >10 
Murzi et al,19  
2015 
Retrospective 
cohort study, 
Monocenter 
Italy 
(Inst.Dat.) 
867 2003-2013 Aortic root, 
ascending and 
aortic arch 
surgery 
Descending 
and thoraco-
abdominal 
aortic surgery 
In-hospital mortality, 
postop complications 
(AMI, stroke, ARF, 
reoperation for 
bleeding, pneumonia, 
pulmonary 
complications, 
delirium, postop 
aortic dissection, 
postop AF, renal 
dysfunction, 
infective, AV block,  
No NA 
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septicaemia, 
myocardial 
infarction) 
Andersen et al,20  
2014 
Retrospective 
case 
controlled, 
Monocenter 
USA 
(Inst.Dat.) 
128 1999-2011 Acute type A 
aortic dissection 
Iatrogenic 
dissection 
30-day/in-hospital 
mortality, 30 day/in-
hospital postop 
complications (AMI, 
stroke, ARF, 
reoperation for 
bleeding, prolonged 
ventilation, delayed 
sternum closure, 
DSWI, new-onset 
dialysis, 
tracheostomy), 
surgeon-specific 
mortality rates, LOS, 
postoperative 
survival 
Yes NA 
Sales et al,21  
2014 
Retrospective 
case 
controlled, 
Monocenter 
Brazil 
(Inst.Dat.) 
332 2003-2010 Thoracic aortic 
surgery, TAAA 
surgery 
 In-hospital mortality, 
postop complications 
(AMI, stroke, ARF, 
reopening for 
bleeding, pneumonia, 
mediastinitis, AV 
block, arrhythmia, 
sepsis, myocardial 
ischemia, pleural 
effusion, low cardiac 
output), LOS 
Yes NA 
Weiss et al,22  
2014 
Retrospective 
cohort study, 
Multicenter 
USA 
(OSHPD) 
1188 1995-2010 TAAA TAA, AAA, pts 
< 18 yr 
In-hospital mortality, 
postop complications 
(AMI, stroke, ARF, 
prolonged intubation, 
ARDS, infection, 
sepsis, paraplegia) 
No LV: <9 
HV: ≥9 
Patel et al,23  
2013 
Retrospective 
cohort study, 
USA 
(MEDPAR) 
7071 2004-2007 TAA-descending 
(intact) 
TAA ruptured, 
TAAA, aortic 
30-day mortality, 
postop complication 
No Open 
surgery: 
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Multicenter dissection, 
ascending 
aortic 
aneurysm, 
concomitant 
cardiac 
procedures, 
use of 
cardioplegia, 
use of HCA 
(ARF, reopening for 
bleeding, cardiac, 
infectious, 
pulmonary, graft), 1-
/3-/5-year 
postoperative 
survival 
LV: ≤8 
HV:>8 
TEVAR: 
LV: ≤8 
HV:>8 
Arnaoutakis et 
al,24  
2013 
Retrospective 
cohort study, 
Multicenter 
USA 
(NIS) 
1865 2005-2009 TAAA (intact) Ruptured-
traumatic-
mycotic-
syphilitic 
aneurysms, 
patients <18 
yr or pts > 99 
yr 
In-hospital mortality, 
postop complications 
(cardiac, AMI, 
nervous, ARF, 
bleeding, paralysis, 
respiratory, digestive, 
visceral vascular, 
bowel resection, 
renal, seroma, 
wound, infectious), 
hospital charges 
No LV: 1 
MV: 1-5 
HV: 5-33 
Chikwe et al,25  
2013 
Retrospective 
cohort study, 
Multicenter 
USA 
(NIS) 
5184 2003-2008 Acute aortic 
dissection 
Lack of 
surgeon 
identification  
In-hospital mortality‡ No Lowest:<3 
Low:>3-8 
High:>8-13 
Highest:>13 
Goodney et al,26  
2013 
Retrospective 
cohort study, 
Multicenter 
USA 
(MP/Sf & 
MDf) 
15305 1998-2007 TAA-Descending Aortic 
dissection, 
TAA 
ascending, 
TAAA, use of 
CPB with HCA, 
debranching 
procedures, 
procedures to 
extend 
endovascular 
landing zone  
30-day mortality, 1-
year mortality and 5-
year mortality 
No Open 
surgery: 
Lowest: 1-4 
LV: 5-8 
MV: 9-15 
HV: 16-46 
Highest:>46 
TEVAR: 
Lowest: 0-1 
LV: 2-3 
MV: 4-8 
HV: 9-17 
Highest:>18 
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Soppa et al,27  
2013 
Retrospective 
cohort study, 
Monocenter 
UK 
(Inst.Dat.) 
163 2005-2011 Aortic root 
dilatation 
Marfan In-hospital mortality, 
postop complications 
(stroke, temporary 
hemofiltration, 
reopening for 
bleeding), LOS, 
follow-up (late 
dilatation, late 
reoperations, late 
death)  
Yes NA 
Tsagakis et al,28 
 2013 
Retrospective 
cohort study, 
Monocenter 
Germany 
(Inst.Dat.) 
124 2004-2011 Acute type A 
aortic dissection 
Pts died 
preoperatively 
30-day mortality, 
postop complications 
(stroke, temporary 
hemofiltration, 
reopening for 
bleeding, 
malperfusion, 
laparotomy, 
peripheral surgery) 
Yes NA 
Hughes et al,29  
2013 
Retrospective 
cohort study, 
Multicenter 
USA  
(STS) 
13358 2004-2007 TAA-ascending/ 
Aortic root 
Aortic 
dissection, 
non-elective 
cases 
30-day/in-hospital 
mortality, postop 
complications 
(stroke, ARF, 
reopening for 
bleeding, prolonged 
ventilation) 
No Lowest:<6 
Low: 6-13 
MV:13-30 
HV: 30-100 
Sakata et al,30  
2012 
Retrospective 
cohort study, 
Multicenter 
Japan 
(JATS) 
14095 2005-2009 Acute type A 
aortic dissection 
 30-day mortality No Lowest:1-4 
Low: 5-9 
MV: 10-14 
High: 15-19 
Highest: 
≥20 
Chavanon et al,31  
2011 
Retrospective 
cohort study, 
Monocenter 
France 
(Inst.Dat.) 
380 1990-2009 Acute type A 
aortic dissection 
Iatrogenic 
dissection, 
chronic 
dissection, 
recurrent 
dissection 
In-hospital mortality Yes NA 
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Gopaldas et al,32  
2010 
Retrospective 
cohort study, 
Multicenter 
USA 
(NIS) 
923 2006-2008 TAA-descending 
(ruptured) 
Vasculitis, 
connective 
tissue 
disorders, 
aortic 
dissection, 
concomitant 
aneurysm,  
patients 
treated with 
both open 
surgery and 
TEVAR 
In-hospital mortality, 
postop complications 
(hemopericardium, 
open cardiac 
massage, procedure-
related 
complications, deep 
venous thrombosis, 
infections, 
mediastinitis, 
neurologic 
complications, 
pneumothorax, 
respiratory 
complications, renal 
complications, 
disposition), LOS 
No LV§ 
HV 
Harris et al,33  
2010 
Retrospective 
case 
controlled, 
Monocenter 
USA 
(Inst.Dat.) 
101 2003-2009 Acute aortic 
dissection 
Iatrogenic 
dissection 
In-hospital mortality, 
time from 
presentation or 
diagnosis to OR 
Yes NA 
Davies et al,34  
2010 
Retrospective 
case 
controlled, 
Monocenter 
USA 
(Inst.Dat.) 
621 2007-2008 Acute aortic 
dissection, 
symptomatic TAA 
and TAAA, AAA 
IMH, aortic 
ulcers, chronic 
aneurysms 
and 
dissections 
In-hospital mortality, 
postop complications 
(AMI, ARF, 
respiratory failure, 
pulmonary 
embolisms, 
pneumonia, 
cardiovascular 
accident, spinal cord 
ischemia, arrhythmia, 
bowel ischemia, 
blood transfusion 
units [n], 
coagulopathy), LOS, 
time to therapy 
Yes NA 
Gazoni et al,35  
2010 
Retrospective 
cohort study, 
USA 
(NIS) 
731 2004-2007 Elective 
TAA+TAAA 
 30-day/in-hospital 
mortality, postop 
No LV: ≤39 
HV: ≥83 
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Multicenter complications 
(stroke, ARF, 
reopening for 
bleeding, prolonged 
ventilation, 
pneumonia), LOS, 
hospital discharge 
Miyata et al,36  
2009 
Retrospective 
cohort study, 
Multicenter 
Japan 
(JACVSD) 
2875 2003-2005 Thoracic aortic 
surgery including 
combined CABG, 
valve surgery or 
other surgical 
operations 
Hospitals <5 
procedures/yr, 
center with 
incomplete 
submission 
data  
30-day/in-hospital 
mortality 
No LV: 5-20¶ 
MV: 20-40 
HV: >40 
Schermerhorn et 
al,37  
2008 
Retrospective 
cohort study, 
Multicenter  
USA 
(NIS) 
2549 1988-2003 TAA-descending TAAA, AA, use 
of 
cardioplegia, 
hypothermia,  
cardiac 
surgery 
debranching 
of epiaortic 
vessels, 
intrathoracic 
bypass, 
pts<18yr 
In-hospital mortality, 
postop complications 
(cardiac, stroke, ARF, 
respiratory, neuro 
non-stroke), LOS 
No LV: 1 
[1,1]** 
MV: 2 [2,3] 
HV: 4 [3,25]   
Knipp et al,38 
2007 
Retrospective 
cohort study, 
Multicenter 
USA 
(NIS) 
3013 1995-2003 Acute type A 
aortic dissection 
 In-hospital mortality No LV: <1 
MV: 1-2.5 
HV: >2.5 
Kazui et al,39 
2007 
Retrospective 
cohort study, 
Multicenter 
Japan 
(JATS) 
10097 2000-2004 Acute type A 
aortic dissection 
 30-day mortality No Lowest:1-4 
Low: 5-9 
MV: 10-14 
High: 15-19 
Highest: 
≥20 
Rigberg et al,40  
2006 
Retrospective 
cohort study, 
Multicenter 
USA 
(OSHPD) 
1010 1991-2002 TAAA Aortic 
dissections 
30-day mortality, 31-
365 days mortality, 1-
year mortality 
No LV: 1 
MV: 2-7 
MV: 7-14 
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Narayan et al,41  
2004 
Retrospective 
cohort study, 
Monocenter 
UK 
(Inst.Dat.) 
296 1992-2003 Ascending and 
aortic arch (+ 
concomitant 
cardiac surgeries) 
 30-day/in-hospital 
mortality, postop 
complications (IABP, 
reopening for 
bleeding, rewiring, 
neurological 
complication 
[transient, 
permanent], renal 
complication), LOS, 1-
/3-year postoperative 
survival 
No NA 
Cowan et al,42  
2003 
 
Retrospective 
cohort study, 
Multicenter 
USA  
(NIS) 
1542 1988-1998 TAAA 
(intact) 
TAAA 
ruptured, 
aortic 
dissections 
In-hospital mortality, 
postop complications 
(cardiac, ARF, 
pulmonary, urinary 
tract, hemorrhage), 
LOS 
No LV: 1 
[1,3]** 
MV: 4 [2,9] 
HV: 12 
[5,31]  
Derrow et al,43  
2001 
Retrospective 
cohort study, 
Multicenter 
USA 
(NIS) 
2934  
(TAAA, 
n=540) 
1993-1997 TAAA (intact), 
renal artery 
bypass, chronic 
mesenteric 
ischemia 
TAAA 
ruptured 
In-hospital mortality, 
postop 
complications, LOS, 
discharge disposition, 
hospital charges 
No LV§ 
HV 
Albrink et al,44  
1994 
Retrospective 
case 
controlled, 
Monocenter 
USA 
(Inst.Dat.) 
30 1986-1990 Blunt thoracic 
aortic transection 
 In-hospital mortality, 
postop complications 
(ARF,  paraplegia, 
pneumonia/sepsis, 
paraparesia, 
recurrent laryngeal 
nerve injury, 
arrhythmia, 
chylothorax) 
Yes NA 
 
Abbreviations: AAA, abdominal aortic aneurysm; AF, atrial fibrillation; AMI, acute myocardial infarction; ARDS, acute respiratory distress syndrome; ARF, acute renal failure; 
AV, atrio-ventricular; CPB, cardiopulmonary bypass; DSWI, deep sternal wound infection; DVT, deep venous thrombosis; HCA, hypothermic circulatory arrest; HV, high 
volume hospital; IABP, intra-aortic balloon pump; IMH, intramural hematoma; Inst.Dat., Institutional Database; LOS, length of stay; LV, low volume hospital; MV, medium 
volume hospital; NA, not available; OR, operating room; PE, pulmonary embolism; TAA, thoracic aorta aneurysm; TAAA, thoracoabdominal aneurysm; TEVAR, thoracic 
endovascular aortic repair. 
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*Data source: JATS=Japanese Association for Thoracic Surgery. JACVSD=Japan Adult Cardiovascular Surgery Database. MEDPAR=Medicare Provider Analysis and Review. 
MP/Sf & MDf=Medicare Physician/Supplier file and Medicare Denominator file. NIS=Nationwide Inpatient Sample. OSHPD=California Office of Statewide Health Planning 
and Development. STS-ACSD=Society of Thoracic Surgeons Adult Cardiac Surgery Database. VCSQI=Virginia Cardiac Quality Initiative.  
†Volume activity defined over the entire study period. 
‡Major postoperative complications listed, but no comparison was made with reference to the hospital or surgeon volume or hospital location or teaching status. 
§Not specified the threshold (cases/year); general definition of LV (vs MV) vs HV hospital only.  
¶Low volume thoracic aortic center performing <5 case/yr excluded (n=2 hospitals).  
**Defined as median [range] of cases. 
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Table S12. Study outcomes stratified by hospital and surgeon volume 
 
Study 
(Author, Year) 
High-Volume 
(HV) 
Low-Volume  
(LV) Mortality (%) 
Re-exploration 
bleeding/ 
tamponade (%) 
Stroke (%) Acute renal failure (%) 
Perioperative 
MI (%) LOS (days) 
Age 
(yr) 
Female 
(%) Pts 
Age 
(yr) 
Female 
(%) Pts HV LV HV LV HV LV HV LV HV LV HV LV 
Hospital volume 
Iribarne et al,18 
2015 
58.7 
(16.2) 33.1 124 
59.5 
(14.6) 32.6 798 12.1 23.4*   9.7 9.5 20.2 30.3* 0.8 5.5* 
13.9 
(11.7) 
14.9  
(15.4) 
Weiss et al,22  
2014  49.2 479  42.6 709 20.4 25.2   7.9 2.6* 28.4 22.4* 12.5 13.0*   
Patel et al,23 
2013  
(open repair) 
72  
(8.1) 49.0 1772 
72  
(8.1) 51.0 1782 11.0 15* 17.0 16.0   20.0 17.0     
Patel et al,23  
2013 
(TEVAR) 
75  
(7.9) 42.0 1758 
75 
(7.7) 43.0 1759 5.5 3.9 13.0 11.0   6.9 5.3     
Chikwe et al,25 
2013   1379   1312 16.4 27.4*           
Hughes et al,29 
2013 59.9 29.2 3404 60.9 30.9 3331 3.4 5.8*   1.9 2.3 4.6 5.7     
Sakata et al,30 
2012   2779   3051 9,7 16.1*           
Gazoni et al,35 
2010 62.5  515 61.0  216 3.7 8.3* 5.4 7.9 4.8 1.4* 4.5 8.3   
8.5 
(10.1) 
11.6 
(17.0)* 
Miyata et al,36 
2009 
69  
(58-75) 30.9 1398 
69  
(61-75) 36.4 481 4.4 9.6*           
Schermerhorn et 
al,37 2008 
68  
(18-92) 42.2 1262 
68  
(21-89) 43.1 685 15.5 21.7*   3.2 2.3 9.8 10.8   
19  
(1-330) 
15  
(15-176)* 
Kazui et al,39  
2007   541   3085 7.9 18.5*           
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Cowan et al,42  
2003  
68.3 
(9.2) 42.0 506 
68.5 
(9.9) 40.0 569 15.0 27.3* 10.3 14.8   13.0 12.3*     
Derrow et al,43 
2001 
69.5 
(8.8)  403 
69.2 
(5.9)  17 18.2 25.0         
19.3 
(18.9) 
21.9  
(20.1) 
Surgeon Volume 
Lenos et al,17 
2015 
62 
(15) 34.7 75 
63  
(14) 32.2 87 4.0 21.8*   2.7 11.5*       
Murzi et al,19  
2014  27.6 460  31.7 407 3.7 2.2 9.6 11.3 2.6 2.5 8.7 10.1 2.2 1.5   
Andersen et al,20 
2014 
54  
(14) 28.0 72 
58  
(15) 30.0 56 2.8 33.9* 4.2 33.9* 5.6 12.5 16.7 26.8 1.4 1.8 12 (12) 10 (12) 
Chikwe et al,25  
2013   938   1130 17.0 27.5*           
Narayan et al,41  
2004 
64  
(52-72) 29.2 130 
60  
(47-68) 29.5 166 10.8 13.9 7.7 7.8 3.8 4.8       
Albrink at al,44  
1994 36.1 13.0 15 35.9 17.0 12 7.0 50*     6.7 41.7*     
 
Abbreviations: LV, low volume; LOS, length of hospital stay; HV, high volume; SD, standard deviation; TEVAR, thoracic endovascular aortic repair. 
 
Values are expressed as mean (±SD) or median (with interquartile range or normal range) for numerical variables, and percentage for categorical variables 
 
*P-value <0.05 for comparison between LV versus HV hospital/surgeon. 
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Table S13. Study outcomes for study with defined a specific thoracic aortic program 
 
Study 
(Author, Year) 
Post-Thoracic Program Pre-Thoracic Program Mortality  (%) 
Re-exploration 
bleeding/ 
tamponade (%) 
Stroke  
(%) 
Acute renal 
failure (%) 
Myocardial 
infarction (%) 
LOS  
(days) 
Age Female % Pts Age 
Female 
% Pts Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre 
Grau et al,16  
2015 62 (12) 22.7 38 63 (12) 50* 16 7.9 12.5 21.2 6.3 2.6 6.3 7.9 6.3   
8.2 
(6) 
13.5 
(11)* 
Andersen et al,20 
2014 54 (14) 28.0 72 58 (15) 30.0 56 2.8 33.9* 4.2 19.6* 5.6 12.5 16.7 26.8 1.4 1.8 
12  
(12) 
10  
(12) 
Sales et al,21 
2014 60 (15) 49.0 175 56 (13)* 51.0 157 9.7 23* 14.3 20.4 4.6 10.9* 2.3 1.9 1.7 1.9 
14.8 
(14.2) 
14.4 
(12.8) 
Davies et al,34 
2010 69 (12) 28.0 173 70 (13) 23.0 133 6.0 4.0   9 7 21 14 2 2 
10  
(6) 
11 
 (8) 
Harris et al,33 
 2010 64 (17) 48.0 71 64 (18) 27.0 30 26.8 33.3           
Albrink et al,44 
1994 36.1 13.0 15 35.9 17.0 12 7.0 50*     6.7 41.7*     
 
Abbreviations: LOS, length of hospital stay; SD, standard deviation. 
 
Values are expressed as mean (±SD) for the numerical variables, and percentage for the categorical variables. 
 
*P-value <0.05 for comparison between pre-thoracic and post-thoracic program introduction. 
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Table S14. Quality assessment of observational studies according to the Newcastle-Ottawa Scale 
 
Study* 
(Author, Year) Selection Comparability Outcome Exposure Total 
Cohort Studies 
  Schaffer et al,12 2015 4 2 3 - 9 
  Schaffer et al,13 2015 4 2 3 - 9 
  Bhatt et al,14 2015 4 2 3 - 9 
  Brat et al,15 2015 2 1 1 - 4 
  Lenos et al,17 2015 3 2 2 - 7 
  Iribarne et al,18 2015 4 2 2 - 8 
  Murzi et al,19 2014 4 0 1 - 5 
  Weiss et al,22 2014 4 0 2 - 6 
  Patel et al,23 2013 4 2 2 - 8 
  Arnaoutakis et al,24 2013 4 1 2 - 7 
  Chikwe et al,25 2013 4 1 2 - 7 
  Goodney et al,26 2013 4 2 2 - 8 
  Soppa et al,27 2013 4 2 3 - 9 
  Tsagakis et al,28  2013 3 0 1 - 4 
  Hughes et al,29 2013 4 2 2 - 8 
  Sakata et al,30 2012 4 1 2 - 7 
  Chavanon et al,31 2011 3 0 2 - 6 
  Gopaldas et al,32 2010 4 2 2 - 8 
  Gazoni et al,35 2010 4 2 2 - 8 
  Miyata et al,36 2009 4 1 2 - 7 
  Schermerhorn et al,37 2008 4 2 2 - 8 
  Knipp et al,38 2007 4 1 2 - 7 
  Kazui et al,39 2007 4 1 2 - 7 
  Rigberg et al,40 2006 4 2 3 - 9 
  Narayan et al,41 2004 3 2 2 - 7 
  Cowan et al,42 2003 4 2 3 - 9 
  Derrow et al,43 2001 4 0 2 - 6 
Mean score 3.8 1.4 2.1 - 7.3 
Case Controlled Studies 
  Grau et al,16 2015 2 2 - 3 7 
  Andersen et al,20 2014  2 2 - 3 7 
  Sales et al,21 2014 2 0 - 2 4 
  Harris et al,33 2010 2 2 - 3 7 
  Davies et al,34 2010 2 2 - 3 7 
  Albrink et al,44 1994 1 1 - 1 3 
Mean score 1.8 1.5 - 2.5 5.8 
 
*A study can be awarded a maximum of 4 points for the Selection category, 2 points for the comparability 
category and 3 points for the Outcome/Exposure categories. Therefore the maximum points a study can obtain 
is 9 which indicates a high quality study. 
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Table S15. List of variables included in the final multivariable model 
  
Study* 
(Author, Year) Adjustement perorfemed Variables included in the final model Reference Adjusted OR (95% CI) 
Iribarne et al,18  
2015 Binary logistic regression Charlson comorbidity score* LV 0.47 (0.27 to 0.82) 
Weiss et al,22 
2014 Binary logistic regression 
Age, sex, race, admission year, Charlson comorbidity index*, 
aneurysm rupture, elective repair, HV centers with ≥ 9 cases per 
year 
LV 0.40 (0.17 to 0.96) 
Hughes et al,29  
2013 Binary logistic regression 
Age, LVEF, BSA, serum creatinine, time trend, active endocarditis, 
need for dialysis, atrial fibrillation, female gender, 
hypertension, immunosuppressive treatment, presence of an IABP, 
inotrope use, peripheral vascular disease, unstable 
angina (no myocardial infarction<7 days), left main disease, aortic 
stenosis, aortic insufficiency, mitral stenosis, mitral insufficiency, 
tricuspid insufficiency, chronic lung disease, cerebrovascular 
disease or cerebrovascular accident, diabetes, number of diseased 
coronary vessels, MI, race, admission status, congestive heart 
failure, NYHA class, reoperation, and concomitant CABG 
LV 0.42 (0.31 to 0.58) 
Chikwe et al,25  
2013 
Binary logistic regression 
(4 distinct model including: 
i) annual thoracic aortic 
dissection surgeon volume; 
ii) annual thoracic aortic 
dissection institution volume; 
iii) annual total cardiac 
surgeon volume; 
iv) annual total cardiac 
institution volume) 
Age, sex, race, payer status, anemia, coagulopathy, congestive 
heart 
failure, chronic pulmonary disease, obesity, renal failure, 
cerebrovascular disease, hypertension, peripheral vascular 
disease, valve disorders, diabetes, ischemic heart disease, 
previous cardiac surgery, concomitant CABG, smoking history, 
hospital location, hospital bed size, and teaching status, annual 
thoracic annual thoracic aortic dissection surgeon 
volume, the second model included annual thoracic aortic 
dissection institution volume, the third model included 
annual total cardiac surgeon volume, and the fourth model 
included annual total cardiac institution volume 
HV 2.21 (1.72 to 2.86) 
Patel et al,23  
2013 Binary logistic regression n/a 
HV  
(open repair) 1.4 (1.1 to 1.8) 
Gazoni et al,35  
2010 Binary logistic regression n/a LV 0.41 (0.18 to 0.92) 
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Miyata et al,36  
2009 
Hierarchical mixed-effects 
logistic regression model 
clinical risk factors, procedure year, clinical events (beta-blocker 
usage), range of replacement (root, ascending, arch, distal aorta, 
descending, thoracoabdominal, abdominal) hospital procedural 
volume, and surgeon volume were set as fixed effects, and sites 
were used as random intercepts 
LV 0.989 
Shermerhorn et al,37 
2008 
Binary logistic regression with 
and without comorbidities Comorbidities HV 1.3 (1.1 to 1.6) 
Cowan et al,42  
2003 Binary logistic regression n/a HV 2.2 (1.6 to 3.1) 
 
Abbreviations: BSA, body surface area; CABG, coronary artery bypass grafting; CI, confidence interval; HV, high volume; IABP, intra-aortic balloon pump; LV, low volume; 
n/a, not available; NYHA, New York Heart Association; OR, Odds ratio. 
 
*List of variables defined in Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and 
validation. J Chron Dis 1987;40:373-83. 
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Supplemental Figures 
 
Figure S1. Adjusted six-month mortality in patients affected by TAD receiving an operation (treated) and in 
those who did not (untreated) by county (HES cohort) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: adj, adjusted; TAD, thoracic aortic disease. 
Number of Patients
Ad
ju
st
ed
 6
-m
on
th
 m
or
ta
lit
y 
ra
te
 (%
)
Number of Patients
Ad
ju
st
ed
 6
-m
on
th
 m
or
ta
lit
y 
ra
te
 (%
)
Treated patients
Untreated patients
D
ow
nloaded from
 http://ahajournals.org by on January 24, 2019
40 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z AA AB AC
Root/Ascending Aorta Aortic Arch Descending Aorta Thoracoabdominal Aorta
CENTRE
%
 o
f c
en
tr
e 
ac
tiv
ity
Figure S2. Centre activity by the most distal aortic segment (NACSA dataset) 
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Figure S3. Correlation between the hospital activity (number of cases) and in-hospital mortality (NACSA 
dataset) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For the regression line in the root and ascending category, r2=0.13, in the aortic arch category r2=0.01. Because 
of the small number in each sub-groups, and for the purposes of the present analysis descending thoracic and 
thoracoabdominal procedures were grouped together, leaving a r2 value of 0.07. In all of the categories, the 
OLS regression lines indicate that a trend towards decreasing mortality was observed in centres with HV 
activity. Abbreviations: HV, high volume (centre); OLS=ordinary least squares. 
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Figure S4. PRISMA flow chart of search strategy11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional record 
identified though 
additional sources  
1 
Articles reviewed for more 
detailed evaluation 
(including cross references) 
5907 
Full-text articles assessed  
for eligibility 
70 
Studies included for 
qualitative synthesis 
33 
Studies included for 
quantitative synthesis 
(meta-analysis) 
22 
Records excluded after 
duplicates removed, title review  
(case reports, editorials, other 
surgeries, inappropriate patient 
 
6897 
Titles excluded  
(other surgeries, case reports, 
case series, editorial/reviews, 
irrelevant)   
5837 
Full-text articles excluded 
Duplicate    2 
No outcome/inappropriate 6 
Editorial not identified before  1 
No thoracic aorta disease  10 
Irrelevant   18 
37 
Records identified 
through database 
searching  
12803 
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 Figure S5. Funnel plots showing the absence of publication bias  
P=0.193 
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Figure S6. Forest plot for high-volume versus low-volume hospitals on operative mortality according to the 
primary aortic pathology (upper panel), and forest plot reporting risk adjusted estimates for high- versus low-
volume hospitals on operative mortality according to the primary aortic pathology (lower panel)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ADA, acute aortic dissection; CI, confidence interval; OR, odds ratio.  
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Figure S7. Forest plots comparing the effect of hospital volume for secondary outcomes 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CI=confidence interval; OR=odds ratio.  
 
 
 
 
 
Abbreviations: CI, confidence interval; OR, odds ratio. 
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Figure S8. Forest plots comparing the effect of a multidisciplinary TAD program presence on outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: CI, confidence interval; OR, odds ratio.  
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Figure S9. Forest plots comparing the effect of surgeon volume for hospital mortality and secondary outcomes  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: CI, confidence interval; OR, odds ratio.  
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Figure S10. Forest plots comparing the effect of hospital status on hospital mortality 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: CI, confidence interval; OR, odds ratio.  
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